var title_f1_60_1984="Pneumatic compression boots 2";
var content_f1_60_1984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumatic compression boots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (B) Devices may wrap around the entire leg or alternately just the feet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1984=[""].join("\n");
var outline_f1_60_1984=null;
var title_f1_60_1985="Misconstruction short Roux-en-Y limb misconstruction";
var content_f1_60_1985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Short Roux limb misconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1985=[""].join("\n");
var outline_f1_60_1985=null;
var title_f1_60_1986="Testing for HIV";
var content_f1_60_1986=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Testing for HIV (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/60/1986/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1986/contributors\" id=\"au136\">",
"       John G Bartlett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/60/1986/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1986/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/60/1986/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1986/contributors\" id=\"de8449\">",
"       Allyson Bloom, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/60/1986?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIV TESTING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Human immunodeficiency virus (HIV) testing is used to determine if you are infected with HIV. Many individuals who are at the highest risk for HIV have not been tested, usually because they do not realize that they are at risk. Others avoid testing because they are worried about the possibility of a positive test result.",
"    </p>",
"    <p>",
"     However, testing is encouraged because treatment for HIV is highly effective and early diagnosis can improve your chances of living longer and being healthier. Furthermore, knowing your HIV status can greatly reduce your risk of passing HIV to others if you take precautions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS HIV?",
"     </span>",
"    </p>",
"    <p>",
"     HIV is a virus that weakens your body's immune system, making it difficult to fight infections and certain cancers. People who are infected with HIV may have no signs or symptoms of their illness, but can still pass the infection to others through sexual contact or through exposure to contaminated needles. If HIV is not treated, you will eventually become very ill and may die. The advanced stage of HIV infection is called AIDS (acquired immune deficiency syndrome).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RISK FACTORS FOR HIV INFECTION",
"     </span>",
"    </p>",
"    <p>",
"     Nearly all HIV infections are acquired through sexual contact or exposure to contaminated needles.",
"    </p>",
"    <p>",
"     You are at risk for getting HIV from sex if you have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Had a sexually transmitted disease",
"      </li>",
"      <li>",
"       Had a sexual partner infected with HIV",
"      </li>",
"      <li>",
"       Been a victim of sexual assault (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"        \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Had unprotected sex with multiple partners",
"      </li>",
"      <li>",
"       Exchanged sex for money or drugs or have sex partners who do",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You are at risk for exposure to HIV through contaminated needles if you have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Injected drugs with shared needles or \"works\"",
"      </li>",
"      <li>",
"       Been accidently stuck with a needle or sharp in a healthcare facility",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Many people who have HIV have not been tested because they do not consider themselves at risk for infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Who should be tested for HIV",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention recommend HIV testing for everyone between age 13 and 64 years. There are two reasons for this recommendation:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The treatment of HIV is highly effective. People with HIV can live a nearly normal lifetime with currently available drugs. This treatment is most effective when it is started early in the course of the disease, before symptoms develop.",
"      </li>",
"      <li>",
"       Treating HIV can help prevent the spread of infection to others. If you know you are infected, you can change your behavior so you are less likely to put other people at risk.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HIV TESTING METHODS",
"     </span>",
"    </p>",
"    <p>",
"     There are several methods to test for HIV. All positive tests are confirmed with another test.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32039541\">",
"     <span class=\"h2\">",
"      Rapid tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rapid tests for HIV use saliva or blood from a finger prick. These tests provide results within 5 to 40 minutes and are useful because they do not require that you go back on another day for your results. A positive result requires another test to confirm the result, but most positive test results will be confirmed with additional testing. A negative test does not have to be confirmed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32039553\">",
"     <span class=\"h2\">",
"      Standard tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The standard HIV test uses a sample of blood taken from a vein. The results are usually available in a few days.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Anonymous testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anonymous testing allows you to be tested without disclosing your identity, and is offered in some areas. To locate a clinic that provides anonymous HIV testing in the United States, call 1-800-750-2016.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Home testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Home test kits provide accurate and anonymous results and are available in most pharmacies. The kit requires a small sample of blood, obtaining by pricking the finger. The blood is blotted on a filter strip and mailed to a lab. The lab performs the test and calls you with the result. The results of the test are confidential and are not reported to anyone but you.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HIV TESTING PROCEDURE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Frequency of testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention recommend an HIV test for all people between age 13 and 64, and a repeat test if you have new risk factors, such as a new sexual partner. People who are at high risk for HIV, such as men who have sex with men, injection drug users, and those with multiple sex partners or a partner known to be HIV- infected should be tested every 6 to 12 months.",
"    </p>",
"    <p>",
"     If you are worried that you were exposed to HIV recently, you should be tested now, with a repeat HIV test at 6, 12, and 24 weeks after the potential exposure. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"      \"Patient information: Symptoms of HIV infection (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      HIV TEST RESULTS",
"     </span>",
"    </p>",
"    <p>",
"     Test results are reported as being positive, negative, or indeterminate. The chances of having an inaccurate result are very small.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Negative",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your test is negative, you are unlikely to be infected with HIV. However, if you were exposed to HIV recently, you should be retested six weeks, three months, and six months after the suspected exposure. The first test may be negative if your body has not yet made antibodies to the HIV virus, which can take up to six months. Detection of early HIV infection is important because that is the time when transmission through sex is most likely because the virus levels are so high.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Positive",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your first HIV test is positive, the result needs to be confirmed with further tests. False positive results are uncommon. About a third of patients who are tested for HIV do not return to find out their confirmatory test results. This is a major problem since untreated infection can lead to serious complications and a risk of transmitting infection to others.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Indeterminate",
"     </span>",
"     &nbsp;&mdash;&nbsp;An indeterminate result occurs when your result is not clearly positive or negative. The final result usually depends upon your risk of having HIV. In people at low risk for HIV infection, approximately 1 in 5000 results (0.02 percent) are indeterminate. Persons at high risk for HIV who have an indeterminate result are in the early stages of HIV infection, and subsequent tests will be positive. Less often, a person who is basically healthy can have an indeterminate result for unknown reasons, and subsequent tests will be negative.",
"    </p>",
"    <p>",
"     If you have an indeterminate result, you will need further testing, as determined by an HIV specialist; a simple blood test will give an answer in just a couple of days or less. While awaiting the results of further testing, you should take precautions to avoid transmitting your potential infection to others. This includes discussing the possibility of infection with any sexual partners and use of a condom with every sexual encounter. You should also avoid sharing razors, toothbrushes, and any injection drug equipment (needles, syringes).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PREVENT HIV",
"     </span>",
"    </p>",
"    <p>",
"     In addition to testing, you should learn how to prevent HIV infection. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Encourage your sexual partners to be tested for HIV.",
"      </li>",
"      <li>",
"       Use a latex or polyurethane condom with every sexual encounter.",
"      </li>",
"      <li>",
"       Do not use drugs or alcohol that can affect your judgment about sexual activities.",
"      </li>",
"      <li>",
"       Do not share needles and syringes that have been used by other IV drug users.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379045\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379052\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/31/18931?source=see_link\">",
"      Patient information: Blood or body fluid exposure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379096\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/0/7170?source=see_link\">",
"      Patient information: Symptoms of HIV infection (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7379113\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional Level Information:",
"     </span>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16712?source=see_link\">",
"      Screening laboratory tests in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     and",
"     <a class=\"external\" href=\"file://www.hivtest.org/\">",
"      www.hivtest.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       CDC (Centers for Disease Control and Prevention) National AIDS Hotline",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;English: (800) 342-2437",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Spanish: (800) 344-7432",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases (NIAID)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Treatment Information Service",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 448-0440",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hivatis.org/\">",
"      www.hivatis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       AIDS Clinical Trials Information Service (ACTIS)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 874-2572",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.actis.org/\">",
"      www.actis.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://aids.about.com/forum\">",
"      file://aids.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/60/1986/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/60/1986?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/1\">",
"      Wright AA, Katz IT. Home testing for HIV. N Engl J Med 2006; 354:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/2\">",
"      Greenwald JL, Rich CA, Bessega S, et al. Evaluation of the Centers for Disease Control and Prevention's recommendations regarding routine testing for human immunodeficiency virus by an inpatient service: who are we missing? Mayo Clin Proc 2006; 81:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/3\">",
"      U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/4\">",
"      Chou R, Smits AK, Huffman LH, et al. Prenatal screening for HIV: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/5\">",
"      Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/6\">",
"      Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/7\">",
"      Kates J, Levi J. Insurance coverage and access to HIV testing and treatment: considerations for individuals at risk for infection and for those with undiagnosed infection. Clin Infect Dis 2007; 45 Suppl 4:S255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/8\">",
"      Fenton KA. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis 2007; 45 Suppl 4:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1986/abstract/9\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_60_1986=[""].join("\n");
var outline_f1_60_1986=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIV TESTING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS HIV?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RISK FACTORS FOR HIV INFECTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HIV TESTING METHODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HIV TESTING PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           HIV TEST RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PREVENT HIV",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_60_1987="Jobes test of supraspinatus strength";
var content_f1_60_1987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Jobe's test of supraspinatus strength",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Jobe's test (or the \"empty can\" test) assesses supraspinatus function. The patient places a straight arm in about 90 degrees of abduction and 30 degrees of forward flexion, and then internally rotates the shoulder completely. The clinician then attempts to adduct the arm while the patient resists. Pain without weakness suggests tendinopathy; pain with weakness is consistent with tendon tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1987=[""].join("\n");
var outline_f1_60_1987=null;
var title_f1_60_1988="Oxygen face masks";
var content_f1_60_1988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Venturi face masks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High flow Venturi oxygen masks yield a precise fraction of inspired oxygen by use of a Venturi valve. The size of the valve aperture ensures that specific proportions of oxygen and entrained air are mixed to obtain a fixed oxygen concentration in quantities that exceed the full ventilatory requirement. In contrast, low flow oxygen masks do not provide the entire ventilatory requirement because air is drawn in through the loosely fitting mask in an uncontrolled fashion to supplement the oxygen flow rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bateman, NT, Leach, RM, BMJ 1998; 317:798.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1988=[""].join("\n");
var outline_f1_60_1988=null;
var title_f1_60_1989="Bronchopulm aspergillosis PA";
var content_f1_60_1989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic bronchopulmonary aspergillosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows example of bronchial pattern: several dilated bronchi are filled with mucus and form V- shaped and inverted Y- shaped opacities characteristic of mucoid impaction in the right upper lobe and both lower lobes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1989=[""].join("\n");
var outline_f1_60_1989=null;
var title_f1_60_1990="Overview of thyroid nodule formation";
var content_f1_60_1990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of thyroid nodule formation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1990/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1990/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1990/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1990/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1990/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/60/1990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the prevalence, risk factors, risk of cancer, and etiology of thyroid nodules. An understanding of these factors is essential in developing a reasonable diagnostic approach to patients with these thyroid nodules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodularity of thyroid tissue is extremely common. In a large population study (Framingham, MA), as an example, clinically apparent thyroid nodules were present in 6.4 percent of women and 1.5 percent of men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/1\">",
"     1",
"    </a>",
"    ]. These figures significantly underestimate the true frequency of this disorder, as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In surveys of unselected subjects using ultrasonography, 20 to 76 percent of women had at least one thyroid nodule [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. In Germany, an area of relative iodine deficiency, 96,278 screening ultrasounds found thyroid nodules or goiter in 33 percent of men and 32 percent of women; nodules over 1 cm were found in 11.9 percent of the population [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The prevalence of nodular goiter increased with age from 2.7 and 2.0 percent in women and men aged 26 to 30 years, to 8.7 and 6.7 percent in women and men aged 36 to 40 years, to 14.1 and 12.4 percent in women and men aged 45 to 50 years, and to 18.0 and 14.5 percent in women and men over age 55 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In several autopsy surveys, 37 to 57 percent of patients had thyroid nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with a single palpable nodule, from 20 to 48 percent had additional nodules as detected by ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, while many nodules are detected because of their size or anterior position in the neck, or the skill of the clinician performing the examination, most thyroid nodules are not clinically recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATE OF CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless thyroid nodules, single or multiple, cause obstruction or are cosmetically disturbing, their mass alone does not cause trouble. The main concerns then are: (1) whether or not they are cancers or, if they are, whether they are lethal, and (2) whether or not they cause thyroid dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most thyroid nodules are benign. Surgical series suggesting that 20 to 40 percent of thyroid nodules are cancers all had significant selection bias. Two reports probably provide a more accurate estimate of the true frequency of thyroid cancer among patients with thyroid nodules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a community hospital in North Carolina where most patients with nodules were referred for surgery without benefit of biopsy, 6.5 percent of excised nodules were cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Catania, Italy, 2327 patients presenting with nodules were evaluated by fine needle aspiration biopsy, and 391 were selected for surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/9\">",
"       9",
"      </a>",
"      ]. Cancers were found in 28 percent of the surgical specimens, which represented only 5 percent of all nodules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in Boston, among patients referred to a thyroid practice, the rate of malignancy in thyroid nodules was 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differentiated thyroid cancers (papillary and follicular), which account for about 90 percent of all thyroid cancers, usually have a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/11\">",
"     11",
"    </a>",
"    ]. This is particularly true in younger patients; as an example, the long-term (25-year) mortality of patients under age 40 years with papillary cancers was less than 2 percent after primary surgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of occult papillary thyroid microcarcinomas (less than 1 cm in size) is much higher. In the United States, as an example, 6 to 13 percent of all thyroid glands studied at autopsy contain a papillary microcarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The prevalence is substantially higher in some other countries, reaching 36 percent in Finland [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, microcarcinomas are common and are little threat to life.",
"   </p>",
"   <p>",
"    However, the natural history of microcarcinomas is uncertain. Approximately 15 percent of all differentiated thyroid cancers may behave in an aggressive manner [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/11\">",
"     11",
"    </a>",
"    ]. They can metastasize and, in older patients who present with a cancer that invades through the thyroid capsule, the long-term mortality is 35 to 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Anaplastic carcinomas, some medullary cancers, and thyroid lymphomas are also associated with higher mortality, but are encountered less commonly than differentiated thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors for the development of thyroid cancer have been identified, including age, sex, and history of thyroid irradiation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid nodularity increases with age [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/6\">",
"       6",
"      </a>",
"      ]. The presence of a thyroid nodule in a child is twice more likely to be a cancer than if it was in an adult [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with thyroid nodules, the rate of cancer is twice as high in men than women (8 versus 4 percent), and it is higher in adults over age 60 and under age 30 years than in those aged 30 to 60 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A history of radiation treatment to the head and neck region to treat acne, inflammation of the tonsils or adenoids, or thymic enlargement is associated with an increased incidence of thyroid nodularity and cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/18\">",
"       18",
"      </a>",
"      ]. In two large series, 20 to 27 percent of patients had thyroid nodularity, and 30 to 33 percent of the nodules were cancers; however, some were microcarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. There is no evidence that radiation-associated thyroid cancers are more aggressive than other thyroid cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/18,21\">",
"       18,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematopoietic stem cell transplantation increases the RR for thyroid cancer to 3.26; if transplantation occurred prior to age 10, the RR was 24.6 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF NODULE FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of thyroid nodules are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57701 \" href=\"UTD.htm?8/25/8604\">",
"     table 1",
"    </a>",
"    ). The possible role of oncogenes and tumor suppressor genes in the pathogenesis of these lesions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors associated with an increased risk of thyroid nodules and goiter include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking, especially in areas of mild iodine deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alcohol consumption is associated with thyroid enlargement, more so in women [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IGF-I levels &mdash; associated with nodules in men and goiter in both men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uterine fibroids &mdash; in one report, women with fibroids had a twofold increased risk of thyroid nodules compared to women with a normal uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors associated with a possible decreased risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral contraceptive use [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of statins (associated with a reduced risk of nodules on ultrasound) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Macrofollicular nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign macrofollicular thyroid nodules represent two distinct processes: true monoclonal adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/29\">",
"     29",
"    </a>",
"    ] and colloid nodules in a multinodular goiter. Most of the latter nodules are also monoclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]; they represent the expansion of relatively clonogenic cells, which replicate in nodular fashion. Both polyclonal and monoclonal nodules appear similar on fine needle aspiration (macrofollicular) and are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Follicular neoplasms (microfollicular adenomas)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular neoplasms (microfollicular or cellular \"adenomas\") represent a unique diagnostic problem. They differ from follicular carcinomas only by their lack of capsular or vascular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Thus, the diagnosis of follicular cancer in situ does not exist, because vascular or capsular invasion is required to make the diagnosis of follicular cancer. Microfollicular lesions are usually excised to exclude cancer, unless they can be shown to have autonomous function as demonstrated by thyroid scintigraphy. Fine needle aspiration biopsy of autonomous nodules may demonstrate a microfollicular pattern, but these nodules are virtually always benign [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Thyroid scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multinodular goiters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of goitrogenesis is distinct from true neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/30,32,33,35\">",
"     30,32,33,35",
"    </a>",
"    ]. It was, therefore, assumed that multinodular goiters were unlikely to contain a cancer. Several studies have suggested that the frequency of cancer in nodular goiters is about 25 to 60 percent of that in solitary nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a retrospective study of patients with multinodular goiter with one or more dominant nodules who underwent ultrasound-guided fine needle aspiration biopsy found that 5 percent had thyroid cancers, which is the frequency in patients with solitary nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/39\">",
"     39",
"    </a>",
"    ]. In another study, the risk of malignancy was similar in a patient with a single or multiple nodules, but the risk of malignancy was higher in a solitary nodule than in a non-solitary nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1990/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, a dominant nodule in a multinodular goiter should be evaluated as if it were a single nodule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=see_link\">",
"       \"Patient information: Thyroid nodules (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=see_link\">",
"       \"Patient information: Multinodular goiter (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=see_link\">",
"       \"Patient information: Thyroid nodules (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5375075\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular thyroid tissue is extremely common. In one study, clinically apparent thyroid nodules were present in 6.4 percent of women and 1.5 percent of men. However, in surveys of unselected subjects using ultrasonography, 20 to 76 percent of women had at least one thyroid nodule. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most thyroid nodules are benign. Thyroid cancer occurs in 5 to 15 percent of thyroid nodules. The incidence depends in part upon age, gender, radiation exposure, and family history. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rate of cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major causes of benign thyroid nodules are multinodular goiter, Hashimoto&rsquo;s thyroiditis, and follicular adenomas (",
"      <a class=\"graphic graphic_table graphicRef57701 \" href=\"UTD.htm?8/25/8604\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology of nodule formation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/1\">",
"      Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968; 69:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/2\">",
"      Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 1994; 154:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/3\">",
"      Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology 1991; 181:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/4\">",
"      Reiners C, Wegscheider K, Schicha H, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 2004; 14:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/5\">",
"      Rice, CO. Incidence of nodules in the thyroid. Arch Surg 1932; 24:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/6\">",
"      MORTENSEN JD, WOOLNER LB, BENNETT WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955; 15:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/7\">",
"      Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/8\">",
"      Werk EE Jr, Vernon BM, Gonzalez JJ, et al. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/9\">",
"      Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) 1989; 121:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/10\">",
"      Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006; 91:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/11\">",
"      Sisson JC. Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 1989; 18:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/12\">",
"      Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/13\">",
"      Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 1974; 34:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/14\">",
"      Ludwig, G, Nishiyama, RH. The prevalence of occult papillary thyroid cancer in 100 consecutive autopsies in an American population. Lab Invest 1976; 34:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/15\">",
"      Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A \"normal\" finding in Finland. A systematic autopsy study. Cancer 1985; 56:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/16\">",
"      Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/17\">",
"      Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992; 93:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/18\">",
"      Schneider AB, Shore-Freedman E, Ryo UY, et al. Radiation-induced tumors of the head and neck following childhood irradiation. Prospective studies. Medicine (Baltimore) 1985; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/19\">",
"      Favus MJ, Schneider AB, Stachura ME, et al. Thyroid cancer occurring as a late consequence of head-and-neck irradiation. Evaluation of 1056 patients. N Engl J Med 1976; 294:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/20\">",
"      Cerletty JM, Guansing AR, Engbring NH, et al. Radiation-related thyroid carcinoma. Arch Surg 1978; 113:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/21\">",
"      Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 2003; 97:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/22\">",
"      Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007; 25:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/23\">",
"      Knudsen N, B&uuml;low I, Laurberg P, et al. Association of tobacco smoking with goiter in a low-iodine-intake area. Arch Intern Med 2002; 162:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/24\">",
"      Valeix P, Faure P, Bertrais S, et al. Effects of light to moderate alcohol consumption on thyroid volume and thyroid function. Clin Endocrinol (Oxf) 2008; 68:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/25\">",
"      V&ouml;lzke H, Friedrich N, Schipf S, et al. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab 2007; 92:4039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/26\">",
"      Spinos N, Terzis G, Crysanthopoulou A, et al. Increased frequency of thyroid nodules and breast fibroadenomas in women with uterine fibroids. Thyroid 2007; 17:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/27\">",
"      Knudsen N, B&uuml;low I, Laurberg P, et al. Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women. Clin Endocrinol (Oxf) 2002; 57:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/28\">",
"      Cappelli C, Castellano M, Pirola I, et al. Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. Clin Endocrinol (Oxf) 2008; 68:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/29\">",
"      Aeschimann S, Kopp PA, Kimura ET, et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 1993; 77:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/30\">",
"      Ramelli F, Studer H, Bruggisser D. Pathogenesis of thyroid nodules in multinodular goiter. Am J Pathol 1982; 109:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/31\">",
"      Apel RL, Ezzat S, Bapat BV, et al. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 1995; 4:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/32\">",
"      Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/33\">",
"      Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993; 118:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/34\">",
"      Nelson RL, Wahner HW, Gorman CA. Rectilinear thyroid scanning as a predictor of malignancy. Ann Intern Med 1978; 88:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/35\">",
"      Thomas GA, Williams D, Williams ED. The clonal origin of thyroid nodules and adenomas. Am J Pathol 1989; 134:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/36\">",
"      CERISE EJ, RANDALL S, OCHSNER A. Carcinoma of the thyroid and nontoxic nodular goiter. Surgery 1952; 31:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/37\">",
"      McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in solitary cold nodules and in multinodular goiters. Surgery 1986; 100:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/38\">",
"      Franklyn JA, Daykin J, Young J, et al. Fine needle aspiration cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. BMJ 1993; 307:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1990/abstract/39\">",
"      Tollin SR, Mery GM, Jelveh N, et al. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 2000; 10:235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7863 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1990=[""].join("\n");
var outline_f1_60_1990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5375075\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATE OF CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY OF NODULE FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Macrofollicular nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Follicular neoplasms (microfollicular adenomas)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multinodular goiters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5375075\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/25/8604\" title=\"table 1\">",
"      Major causes of thyroid nodules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/12/30914?source=related_link\">",
"      Patient information: Multinodular goiter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/16/18691?source=related_link\">",
"      Patient information: Thyroid nodules (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=related_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_60_1991="Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization";
var content_f1_60_1991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1991/contributors\">",
"     George AW Bruyn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1991/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1991/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1991/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/60/1991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography, sometimes referred to as ultrasound (US) imaging or sonography, is an imaging modality that utilizes reflected pulses of high frequency (ultrasonic) sound waves to assess soft tissues, cartilage, bone surfaces, and fluid containing structures. US imaging, at one time the sole province of radiologists, is becoming more widely available in rheumatology clinics and in other ambulatory and emergency settings. However, the widespread use of ultrasonography by clinicians who diagnose and treat musculoskeletal disorders has been hampered by questions related to the reliability, validity, standardization, methodology, and ability to detect changes over time. These issues and technical aspects of musculoskeletal US are addressed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of US to assess patients with rheumatic diseases in the clinic was fostered by the development of compact real-time US systems in the 1980s. Synovitis of the knee was the earliest musculoskeletal disorder assessed ultrasonographically in the clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrasonographic assessment of synovitis of the small joints of the hands in patients with rheumatoid arthritis (RA) followed by a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/2\">",
"     2",
"    </a>",
"    ]. Availability in the 1990s of high-resolution transducers made detailed assessment of superficial structures feasible.",
"   </p>",
"   <p>",
"    The nomenclature, technical considerations, validity, and reliability of musculoskeletal ultrasonography are discussed here. Imaging modalities generally used to diagnose disorders of the musculoskeletal system and guidelines for selecting imaging studies (eg, plain film radiography, computed x-ray tomography [CT scan], magnetic resonance imaging [MRI], and ultrasonography) for selected musculoskeletal problems are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link\">",
"     \"Radiologic evaluation of the painful hip in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=see_link\">",
"     \"Radiologic evaluation of the painful shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of US to screen for, to diagnose, and to monitor the response of osteoporosis to treatment requires dedicated, special purpose devices rather than US imaging systems to assess bone mineral content. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for osteoporosis\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE AND CONVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various terms are used to describe ultrasonographic equipment, transducer and image orientation, normal and abnormal features in acquired images, and artifacts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types of ultrasonography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     B-mode US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brightness (B)-mode US is the precursor of gray scale US and is limited to the definition of boundaries of structures and to the differentiation of fluid from solid. Only echoes surpassing a threshold level of intensity are displayed with a uniform brightness on the image screen. B-mode US has largely been replaced by gray scale technology. (See below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gray scale US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gray scale US includes different intensities of echoes and displays them in black, white, and various shades of gray. Although an improvement on B-mode display, gray-scale US cannot differentiate between fibrous synovial tissue and active synovitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Doppler US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler US relies technologically on the Doppler principle, which states that sound waves increase in frequency when they reflect from objects (eg, red blood cells) moving toward the transducer and decrease when they reflect from objects moving away.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Color Doppler US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color Doppler ultrasonography (CDS) applies the Doppler effect combined with real-time imaging. The information from Doppler US is integrated in the gray scale image as a color signal. This signal indicates the direction of blood-flow. Red signals indicate flow that is directed toward the US probe while blue signals indicate flow that is directed away from the probe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Duplex US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex US is the combination of real-time imaging and Doppler US. It depicts both the anatomical image with color signals and the Doppler curves. In addition, this technique allows for estimation of the velocity of flow from a combination of the Doppler frequency shift and the beam angle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Power Doppler US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Power Doppler sonography (PDS) displays the total integrated Doppler signal in color. The sensitivity of PDS for small vessels and for slow blood flow is greater than duplex US. PDS shows hyperemia in inflamed tissues. The amount vascularity present is usually assessed subjectively from the PDS image. The percentage flow on PDS can be scored semi-quantitatively on a scale of 0 to 3. Grade 0 represents no signal on PDS, 1 represents &lt;10 percent, 2 represents 10 to 50 percent, and 3 represents &gt;50 percent. The amount of Doppler signal may vary from machine to machine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transducer orientation and image presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonographic scans are defined by two views, namely a transverse view or short axis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58273 \" href=\"UTD.htm?29/58/30626\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63350 \" href=\"UTD.htm?19/32/19983\">",
"     figure 1",
"    </a>",
"    ) and a longitudinal view or long axis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74216 \" href=\"UTD.htm?39/3/39988\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71359 \" href=\"UTD.htm?21/50/22306\">",
"     figure 2",
"    </a>",
"    ). Transverse views are similar to axial views obtained by CT scan or by MRI.",
"   </p>",
"   <p>",
"    The following orientations of patient, ultrasonographer, and images are suggested standards to aid image acquisition, presentation, and communication of findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient sits or lies at the right side of the sonographer.",
"     </li>",
"     <li>",
"      The sonographer looks at the patient from a caudal to rostral orientation.",
"     </li>",
"     <li>",
"      The upper part of the US image corresponds to anatomic areas closer to the probe. This is anterior (ventral) if the patient is supine.",
"     </li>",
"     <li>",
"      The lower part of the image is the area more distal to the probe. This is posterior (dorsal) if the patient is supine.",
"     </li>",
"     <li>",
"      The left side of the image is the left side",
"      <strong>",
"       from the perspective of the sonographer",
"      </strong>",
"      . Thus, the left side of the image represents the right side of the body if the patient is supine or is sitting facing the examiner. Conversely, the left side of the image represents the left side of the body if the patient is prone or is sitting facing away from the examiner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some sonographers prefer to localize the medial (ulnar, tibial) anatomical area always on the left side of the image and the lateral (radial, fibular) anatomical area on the right side of the image to better compare findings of both extremities. We suggest not presenting the images in this way.",
"   </p>",
"   <p>",
"    By convention, the longitudinal view displays proximal (cranial or rostral) anatomy to the left side of the screen and the distal (caudal) anatomical structures to the right (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74216 \" href=\"UTD.htm?39/3/39988\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71359 \" href=\"UTD.htm?21/50/22306\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echogenicity or echo-texture of various musculoskeletal tissues is assessed from the appearance on the display. The echogenicity of a tissue depends not only upon the characteristic of that tissue but also upon the transducer frequency. The characteristics of various elements of the musculoskeletal system as they appear when assessed with probe frequencies between 5 to 15 MHz are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bone surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone surface is typically hyperechoic (ie, bright) with posterior acoustic shadowing. Cortical irregularities can be depicted by ultrasound. As ultrasonic waves are reflected by bone, ultrasonography does not provide any information of anatomical structures that are localized below an intact bone surface. A good example of the echogenic bone surface is apparent at the deepest bright line in the axial view from the lateral aspect of the shoulder. Bone erosions appear as regular or irregular discontinuities of the cortical surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cartilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cartilage is anechoic (ie, black). Hyaline cartilage (ie, articular cartilage) is directly adjacent to the bone surface. The normal surface of hyaline cartilage is regular. Degenerated cartilage may have increased echogenicity and may have an irregular surface. Fibrocartilage (eg, the labrum of the glenohumeral joint or a knee meniscus) is hyperechoic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Synovium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gray-scale echogenicity of synovium is intermediate (ie, between that of cartilage and bone). Synovium in healthy persons usually does not exhibit color Doppler or power Doppler signals. However, US equipment with a high sensitivity for flow signals may show minor flow even in the absence of joint disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal synovial fluid is anechoic material within a joint. It is displaceable, is compressible, and does not exhibit Doppler signal. Synovial fluid is more easily detected when present in increased amounts, as in inflamed joints or tendon sheaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Joint capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The joint capsule is the anatomical structure that forms the boundary between the hypoechoic synovium, the anechoic synovial fluid, or the anechoic cartilage and the periarticular soft tissues, which are usually mid-echoic. Similar to the connective tissue, subcutaneous fat is also mid-echoic and is slightly irregular. It usually appears slightly less echoic (ie, hypoechoic) than the surrounding connective tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tendons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendons are characterized by a fine internal fibrillar pattern. They are slightly hyperechoic if localized perpendicular to the probe. Hypoechogenicity of tendons is an artifact that is referred to as anisotropy. The hypoechogenicity is not due to pathology but is due to scattering of the beam that is not perpendicular to the tendon surface. Scattered sound waves are not captured by the probe, and, thus, the tendon appears dark. Beam obliquity will result in artifactual decreased echogenicity, and the tendon then appears black.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerves are similar in ultrasonographic appearance to tendons. However, they are slightly hypoechoic, and their structure is more dotted and is less fibrillar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscles are predominantly hypoechoic but are sometimes mid- or hyperechoic according to the transducer orientation. Fine intramuscular hyperechoic lines represent the epi- and perimysium; thicker hyperechoic lines represent septae and investing fascia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bursae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bursae are hypoechoic or anechoic depending upon the structures that prevail in the bursae. The small amount of fluid present in a normal bursa may be imperceptible ultrasonographically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ligaments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligaments have a similar echo-texture to that of tendons. However, if they consist of several layers, the fibrillar pattern may run in different directions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution refers to both",
"    <strong>",
"     axial",
"    </strong>",
"    and",
"    <strong>",
"     lateral",
"    </strong>",
"    (horizontal) resolution. Axial resolution is the ability of the US beam to distinguish two objects that lie in the line of the ultrasound beam at different depths. Lateral or horizontal resolution refers to the minimum lateral distance between two objects that can be differentiated and visualized on the display when they lie side to side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Axial resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial resolution is determined primarily by the frequency of the US signal. Higher frequencies, hence shorter wavelengths, produce better axial resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Lateral resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to widening of the sound beam with increasing tissue depth, the lateral resolution decreases with depth. Transducers that are used for musculoskeletal US reach an axial resolution of 0.1 mm and a horizontal resolution of 0.2 mm. Twenty MHz transducers reach an axial resolution power of 0.04 mm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Time or B gain correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US beam strength weakens with increasing depth due to a combination of absorption and scattering of the tissues. Time or B gain correction is used to allow similarly echogenic structures at different depths to appear on the display with roughly equivalent intensity. Time gain compensation applies increasing amplification to the signal generated by echoes returning to the transducer using an exponential function based on the time of flight. The examiner can modify the time gain to optimize the visualization of the tissues in the beam path.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Refraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refraction is an artifact depicting real structures at the wrong position resulting from bending of the US wave between two materials; this phenomenon may be minimized by keeping the incident beam as close as possible to perpendicular to the surfaces of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reverberation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bouncing of the beam back and forth between the transducer and the object gives rise to multiple echoes. Reverberation produces repetitive echoes below a structure (eg, below a metal object such as a prostheses or a needle) introduced into the tissue in the ultrasound beam path. Reverberation can affect color and power Doppler imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Edge shadows",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;edge shadows&rdquo; is used to describe the US phenomenon of hypoechoic areas behind the edge of spherical, fluid-filled structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Comet tail",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Comet tail&rdquo; is used to describe the artifact caused by reverberation, which creates characteristic bands of increased echogenicity deep to the object.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Acoustic shadowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acoustic shadowing occurs when the ultrasound beam hits a highly reflective surface, like bone, air, calcifications, and calculi. Because little of the beam enters the reflective material, the region beyond it appears hypo- or frankly anechoic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Aliasing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aliasing is a Doppler artifact occurring when the Doppler shifts in frequency, which occurs when the velocities of red blood cells are higher than one-half the pulse repetition frequency (PRF) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/5\">",
"     5",
"    </a>",
"    ]. This occurs, for example, in areas of stenosis, where the reduced lumen of the vessel is seen with a red to blue shift. Red represents flow toward the transducer, within the range of the PRF, and blue velocities beyond the range of the PRF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical equipment used for musculoskeletal ultrasonography is essentially the same as that used in other medical disciplines. However, transducers emitting high frequencies have to be connected to the ultrasound machine. Transducers are preferably linear array transducers, not curved array.",
"   </p>",
"   <p>",
"    Older machines offer single frequency transducers, like those of 5 MHz (usually a curved array one), 7.5 MHz, and 10 MHz, the latter typically requiring the use of a standoff water pad to image relatively superficial musculoskeletal structures.",
"   </p>",
"   <p>",
"    Modern US machines are equipped with multifrequency, so-called broadband transducers, usually in the range 5 MHz to 10 MHz, 7.5 MHz to 13 MHz, or even higher. A high frequency transducer with a small footprint is useful to examine small joints. As noted above, the higher is the frequency, the shorter is the wavelength of the ultrasound pulse and the better is the axial resolution.",
"   </p>",
"   <p>",
"    With high frequencies, superficial structures like tendons and small joints including metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints can be studied. A transducer emitting a beam with a wavelength of 7.5 MHz has an axial resolution of 0.4 mm; the lateral resolution is &gt;0.4 mm. Both axial and lateral resolutions of a 7.5 MHz probe are, therefore, insufficient to accurately assess ligaments of 1 to 2 mm thick. Higher frequency probes (eg, 13 MHz) have an axial resolution of 0.12 mm, and those of 20 MHz have one of 0.038 mm. The disadvantage of higher frequencies is poor tissue penetration.",
"   </p>",
"   <p>",
"    Conventional machines show two-dimensional pictures in real time of the area of interest. Advances in technology have led to the development of three-dimensional (3D) ultrasonography for the spatial imaging of structures. High-end machines offer 3D ultrasonography. It acquires the three-dimensional shape of an object, by a single sweep of a transducer. Four-dimensional ultrasonography demonstrates the dynamic motion of 3D imaging. Three-dimensional ultrasonography may become important in delineating the size of erosions or the extent of synovitis. Contrast-enhanced sonography is being assessed as an aid to detecting active synovitis, but its roles in clinical research and in clinical practice have not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     VALIDATION, RELIABILITY, AND STANDARDIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies on validity and reliability of US in patients with rheumatic disease have been published. These have been facilitated by a consensus of experts in the musculoskeletal US field regarding the definitions of RA erosions, synovial fluid, synovial hypertrophy, tenosynovitis, and enthesopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/6\">",
"     6",
"    </a>",
"    ]. Studies performed thus far suggest moderate to good intraobserver reproducibility and variable agreement between observers, which depends, in part, upon the joint examined and upon the feature of disease that is being assessed. Additional data are needed on these test characteristics in patients with various musculoskeletal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/7\">",
"     7",
"    </a>",
"    ]. The following are illustrative of studies of patients with RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the second MCP joints of 55 patients with RA were assessed ultrasonographically by two examiners [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/8\">",
"       8",
"      </a>",
"      ]. The",
"      <strong>",
"       intra",
"      </strong>",
"      observer kappa statistic for the detection of cortical bone erosions on the second MCP joints of 55 RA patients was 0.75, and the",
"      <strong>",
"       inter",
"      </strong>",
"      observer kappa for agreement between two observers was 0.76. All bone erosions that were detected sonographically but that were not visible on radiography corresponded to MRI abnormalities (ie, were true positive findings).",
"     </li>",
"     <li>",
"      In another study, 14 experts examined four regions (shoulder, hand, knee, and foot) in four patients and compared the acquired images with previously performed MRI for synovitis, erosions, bursitis, and tendonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/9\">",
"       9",
"      </a>",
"      ]. The overall kappa was 0.76. However, there was considerable difference between joints, with the kappa statistic ranging from a high of 0.76 for the shoulder to a low of 0.28 for the",
"      <span class=\"nowrap\">",
"       ankle/toes.",
"      </span>",
"      Kappa values for erosions, bursitis, and tendonitis were high, but agreement for synovitis was low. Sensitivity and specificity of the US images compared with MRI was moderate to good.",
"     </li>",
"     <li>",
"      In another study, 23 experts acquired and interpreted images of four joints (shoulder,",
"      <span class=\"nowrap\">",
"       hand/wrist,",
"      </span>",
"      knee, and",
"      <span class=\"nowrap\">",
"       ankle/foot),",
"      </span>",
"      without a set of predefined definitions or scanning method [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/10\">",
"       10",
"      </a>",
"      ]. Overall agreements were 91 percent for joint",
"      <span class=\"nowrap\">",
"       effusion/synovitis",
"      </span>",
"      and tendon lesions, 87 percent for cortical abnormalities, 84 percent for tenosynovitis, 83.5 percent for bursitis, and 83 percent for power Doppler signal; kappa values were good for the",
"      <span class=\"nowrap\">",
"       wrist/hand",
"      </span>",
"      and knee (0.61 and 0.60) and were fair for the shoulder and",
"      <span class=\"nowrap\">",
"       ankle/foot",
"      </span>",
"      (0.50 and 0.54).",
"     </li>",
"     <li>",
"      Another experiment assessed the intra- and interobserver reliability regarding synovitis of small hand joints in RA patients. Seventeen rheumatologist experts in US scored a sequence of 86 images of MCP, PIP, MTP, and wrist joints for the presence or absence of gray scale and power Doppler synovitis according to a predefined (OMERACT) definition. In the follow-up experiment, the experts acquired images of 32 MCP and 32 PIP joints on eight patients with rheumatoid arthritis. Results showed good agreement both between the interobserver and intraobserver interpretation of static images, but the kappa values for the acquisition of images were low [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies concerned reliability of ultrasound detection of shoulder disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/12\">",
"       12",
"      </a>",
"      ] and tenosynovitis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are needed regarding the responsiveness to change for US articular findings and for validation of these observations. In a drug intervention trial, changes of synovial thickness and PD signals were assessed by US. The improvement of both parameters was better in the patient group treated with the combination therapy consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and MTX versus MTX monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1991/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technologic advances have allowed real-time use of ultrasonography to image tendons, bursae, ligaments, cartilage, synovium, synovial fluid, nerves, and bone. B-mode, gray scale, Doppler, color Doppler, duplex Doppler, and power Doppler US are different types of US technologies used for musculoskeletal imaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some standards for orientations of patient, ultrasonographer, and images are suggested to aid in image reading, acquisition, presentation, and communication of findings. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Transducer orientation and image presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different musculoskeletal tissues have different appearances on display, ranging from anechoic (black) for homogeneous fluid to brightly echogenic (white) for the bone surface. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Echogenicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axial and lateral resolutions are generally superior with higher frequency US. Systems used for musculoskeletal US have typical axial and horizontal resolutions of 0.1 mm and 0.2 mm, respectively. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various artifacts may occur and may need to be recognized; these include refraction, reverberation, edge shadows, acoustic shadowing, and aliasing. (See above.)",
"     </li>",
"     <li>",
"      Transducers used for musculoskeletal imaging typically employ multifrequency or broadband linear array probes. The transducer frequency and probe size are determined by the size and depth of the structures of interest. A higher frequency and smaller probe are used for smaller, superficial structures while lower frequencies and larger probes are used for deeper and bigger structures. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Technical considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies of US imaging in rheumatic diseases suggest a moderate to good",
"      <strong>",
"       intra",
"      </strong>",
"      observer reproducibility and variable",
"      <strong>",
"       inter",
"      </strong>",
"      observer agreement that depends, in part, upon the joint examined and upon the feature of disease that is being assessed. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Validation, reliability, and standardization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/1\">",
"      Cooperberg PL, Tsang I, Truelove L, Knickerbocker WJ. Gray scale ultrasound in the evaluation of rheumatoid arthritis of the knee. Radiology 1978; 126:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/2\">",
"      De Flaviis L, Scaglione P, Nessi R, et al. Ultrasonography of the hand in rheumatoid arthritis. Acta Radiol 1988; 29:457.",
"     </a>",
"    </li>",
"    <li>",
"     Bruyn GAW, Schmidt WA. Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, 2nd, Bohn Stafleu van Loghum, Houten 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/4\">",
"      Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/5\">",
"      Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology. Ann Rheum Dis 2008; 67:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/6\">",
"      Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/7\">",
"      Joshua F, Lassere M, Bruyn GA, et al. Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 2007; 34:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/8\">",
"      Wakefield RJ, Gibbon WW, Conaghan PG, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000; 43:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/9\">",
"      Scheel AK, Schmidt WA, Hermann KG, et al. Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR \"Train the trainers\" course. Ann Rheum Dis 2005; 64:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/10\">",
"      Naredo E, M&ouml;ller I, Moragues C, et al. Interobserver reliability in musculoskeletal ultrasonography: results from a \"Teach the Teachers\" rheumatologist course. Ann Rheum Dis 2006; 65:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/11\">",
"      Wakefield RJ, D'Agostino MA, Iagnocco A, et al. The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol 2007; 34:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/12\">",
"      Bruyn GA, Naredo E, M&ouml;ller I, et al. Reliability of ultrasonography in detecting shoulder disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/13\">",
"      Bruyn GA, M&ouml;ller I, Garrido J, et al. Reliability testing of tendon disease using two different scanning methods in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1991/abstract/14\">",
"      Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004; 50:1107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1834 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1991=[""].join("\n");
var outline_f1_60_1991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE AND CONVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types of ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - B-mode US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gray scale US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Doppler US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Color Doppler US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Duplex US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Power Doppler US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transducer orientation and image presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bone surface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cartilage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Synovium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Joint capsule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tendons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Muscles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bursae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Axial resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Lateral resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Time or B gain correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Refraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reverberation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Edge shadows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Comet tail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Acoustic shadowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Aliasing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      VALIDATION, RELIABILITY, AND STANDARDIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1834|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/58/30626\" title=\"diagnostic image 1\">",
"      Transverse view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/3/39988\" title=\"diagnostic image 2\">",
"      Longitudinal view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1834|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/32/19983\" title=\"figure 1\">",
"      Volar structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/50/22306\" title=\"figure 2\">",
"      Artist impression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=related_link\">",
"      Radiologic evaluation of the painful hip in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=related_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_60_1992="Blood smear too thin";
var content_f1_60_1992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blood smear too thin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Suboptimally prepared peripheral blood smear which is too thin. This low power view shows red cells which appear flattened and \"brick like\" in appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jackie Mitus, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1992=[""].join("\n");
var outline_f1_60_1992=null;
var title_f1_60_1993="Urinary tract endometriosis";
var content_f1_60_1993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary tract endometriosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Nicola Berlanda, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Paolo Vercellini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Luigi Fedele, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1993/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/60/1993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30390246\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is defined as the presence of endometrial glands and stroma at extrauterine sites. These ectopic endometrial implants are usually located in the pelvis, but can occur nearly anywhere in the body. Endometriotic lesions of the urinary tract are present in 1 to 2 percent of women with endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ureteral and bladder endometriosis both occur in the urinary tract, they do not frequently coexist and their clinical presentation and management are different. Bladder endometriosis causes urinary discomfort often mimicking recurrent cystitis, but rarely results in severe sequelae. Ureteral endometriosis is often asymptomatic, but can lead to silent loss of renal function.",
"   </p>",
"   <p>",
"    Diagnosis and management of urinary tract endometriosis are reviewed here. General principles of the treatment of endometriosis, as well as endometriosis of the rectovaginal septum, bowel, and thorax, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24858?source=see_link\">",
"     \"Rectovaginal or bowel endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link\">",
"     \"Thoracic endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17036461\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three theories for the pathogenesis of endometriosis. These include spread of endometrial cells from retrograde menstruation, lymphatic or hematogenous dissemination, and coelomic metaplasia. Some experts have suggested that vesical endometriosis represents bladder adenomyosis or may be an extension of adenomyosis from the uterus due to anatomic proximity of the bladder and uterus or imperfect closure of the uterus during a cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep endometriosis is defined as a solid mass situated deeper than 5 mm under the peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/7\">",
"     7",
"    </a>",
"    ]. According to the theory of retrograde menstruation, deep endometriosis is the result of cells implanting in the most dependent areas of the pelvis, such as the spaces anterior and posterior to the uterus. These spaces serve as anatomic shelters that contain endometrial cells and prevent them from being cleared by the usual processes within the peritoneal cavity. The presence of endometrial cells elicits an inflammatory response and, eventually, a fibrotic nodule is originated and buried under the peritoneum.",
"   </p>",
"   <p>",
"    In this model, sheltering structures correspond as follows to sites of deep endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/6,8-13\">",
"     6,8-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterus &ndash; anterior pouch, bladder",
"     </li>",
"     <li>",
"      Rectosigmoid colon &ndash; posterior cul-de-sac (pouch of Douglas), lower third of ureter &nbsp;",
"     </li>",
"     <li>",
"      Ovary &ndash; pelvic sidewall, middle third of ureter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29778329\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract lesions are found in 1 to 2 percent of women with symptomatic endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/14\">",
"     14",
"    </a>",
"    ]. The prevalence of endometriosis in the general population is unknown. The best clinical estimate is 1 to 7 percent of women, based upon data from gross examination of the pelvis in women who have undergone gynecologic surgery that was not performed for typical symptoms of endometriosis (pelvic pain, infertility) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bladder is the most common site of endometriotic lesions of the urinary tract. Among women with urinary tract endometriosis, the prevalence of disease at specific sites are [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bladder &ndash; 85 percent",
"     </li>",
"     <li>",
"      Ureter &ndash; 10 percent",
"     </li>",
"     <li>",
"      Kidney &ndash; 4 percent",
"     </li>",
"     <li>",
"      Urethra &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss only bladder and ureteral endometriosis, since other urinary tract sites are rarely encountered.",
"   </p>",
"   <p>",
"    Urinary tract endometriosis often coexists with disease at other sites. A retrospective series of 1054 women who underwent primary surgery for endometriosis found that 88 percent of women with bladder endometriotic nodules had lesions at other locations, including ovarian endometriomas (45 percent) and other sites of deep endometriosis (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390253\">",
"    <span class=\"h1\">",
"     BLADDER ENDOMETRIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder endometriosis is defined as endometriosis infiltrating the detrusor muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17036718\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriotic lesions of the bladder cause nonspecific urinary symptoms, including urinary frequency, urgency, dysuria, or urinary retention",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/14\">",
"     14",
"    </a>",
"    ]. Occurrence of these symptoms during menses is suggestive of this condition. Hematuria is infrequent, but when present, typically coincides with menses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/21\">",
"     21",
"    </a>",
"    ]. In the vast majority of patients, the ureteral openings are not involved by the vesical nodule and, therefore, hydronephrosis is seldom an issue for women with bladder endometriosis. Endometriosis is commonly associated with infertility, but it is uncertain whether an isolated bladder nodule of the bladder, located away from the adnexa, impacts infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\", section on 'Pathogenesis of infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women with bladder endometriosis are asymptomatic and present with an incidental finding of a bladder nodule on pelvic imaging or at time of pelvic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17036780\">",
"    <span class=\"h2\">",
"     Diagnosis and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is typically diagnosed by direct visualization of implants; biopsy and histologic confirmation is the gold standard. Visualization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy of bladder lesions are accomplished most commonly with cystoscopy, but laparoscopy may be necessary in some cases.",
"   </p>",
"   <p>",
"    Symptoms consistent with bladder endometriosis, particularly in women with known endometriosis at other sites or characteristic symptoms (pelvic pain, dysmenorrhea, dyspareunia, infertility), in combination with a finding of a bladder nodule on ultrasound suggest a diagnosis of vesical endometriosis and warrant further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of bladder endometriosis includes urinary tract infection, interstitial cystitis, and a bladder stone or neoplasm, and symptoms (eg, fever, hematuria) or history relevant to these conditions should be elicited. Urinary testing to rule out infection and other conditions should be guided by the patient&rsquo;s clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949177#H899949177\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic and renal sonography is used to evaluate for a bladder nodule and for hydronephrosis. A finding of ovarian cysts consistent with endometriomas supports the diagnosis of endometriosis, although endometriosis is often not visualized on imaging studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with a bladder nodule, cystoscopy is performed to biopsy the lesion to rule out malignancy and confirm endometriosis (",
"    <a class=\"graphic graphic_picture graphicRef70190 \" href=\"UTD.htm?17/21/17759\">",
"     picture 1",
"    </a>",
"    ). It is also important to assess the distance of the lesion from the ureteral openings to determine whether removal of the lesion requires ureteral surgery. Lesions that are not visible at time of cystoscopy may be evaluable with magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In women with hydronephrosis, radiologic assessment of the ureter is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\", section on 'Diagnosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17036840\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of vesical endometriosis is indicated in symptomatic patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resolution of hydronephrosis. First line treatment is medical therapy, since this approach avoids the risk of surgical complications. The disadvantages of medical therapy are that it must be continued until menopause, when endometriosis typically regresses, and that it is not effective in all women. There are no data comparing medical and surgical therapy, but we reserve surgery for women who have failed or have contraindications to medical therapy, who wish to avoid chronic medical treatment, or who have hydronephrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390260\">",
"    <span class=\"h3\">",
"     Medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy of symptomatic bladder endometriosis is the same as for other sites of the disease. Small case series have reported improvement in symptoms and regression of lesions in women with vesical endometriosis after treatment with oral contraceptives, progestins, and gonadotropin releasing hormone agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the treatment of endometriosis\", section on 'Treatment of pelvic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A tolerable and safe medication should be chosen. We prescribe an oral contraceptive on the usual cyclic regimen (ie, three weeks of therapy followed by a placebo week). If perimenstrual symptoms do not resolve with a cyclic regimen, a continuous schedule may be used. Another first-line treatment that is effective and well tolerated is a low dose progestin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30750173\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive treatment of bladder endometriosis consists of surgical removal of the endometriotic lesion. Full thickness resection of the bladder wall at the site of the lesion is the procedure of choice for women in whom the lesion deeply infiltrates the bladder wall [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/14,28-33\">",
"     14,28-33",
"    </a>",
"    ]. Shaving off the nodule without opening the bladder is reserved for women with lesions that do not fully penetrate the bladder wall [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4814318\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of patients, full thickness resection of the lesion can be performed laparoscopically. In complex cases, ureteroneocystostomy may be required. Preoperative characteristics that suggest the need for an advanced procedure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inferior limit of the endometriotic nodule is less than 2 cm away from the inter-ureteric ridge",
"     </li>",
"     <li>",
"      The patient has already undergone a previous resection of a bladder lesion.",
"     </li>",
"     <li>",
"      There is associated hydronephrosis or possible endometriosis of the ureter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Procedures in such patients are typically performed via laparotomy and should be undertaken only by surgeons with experience with ureteroneocystostomy.",
"   </p>",
"   <p>",
"    At the beginning of the procedure, some surgeons catheterize the ureters via cystoscopy. This is done to make the ureters easy to identify and, thereby, help avoid ureteral injury. Randomized trial data do not support routine use of ureteral catheters for pelvic surgery; however, their use may be warranted in women with sever endometriosis. In our practice, we catheterize patients in whom the distance between the inferior border of the endometriotic lesion and the interureteric ridge is less than 2 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=see_link&amp;anchor=H22#H22\">",
"     \"Urinary tract injury in gynecologic surgery: Prevention\", section on 'Prophylactic ureteral catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the bladder dome, removal of a solitary endometriotic nodule may not require any preliminary dissection. In contrast, endometriotic nodules involving the posterior aspect of the bladder or the vesical base must be mobilized from the surface of the uterus by dissecting the vesicouterine space (",
"    <a class=\"graphic graphic_picture graphicRef79226 \" href=\"UTD.htm?17/31/17905\">",
"     picture 2",
"    </a>",
"    ). Dissection must continue below the caudal margin of the nodule in order to achieve complete resection. The lesion is then excised with cold scissors or electrosurgery (",
"    <a class=\"graphic graphic_picture graphicRef76479 \" href=\"UTD.htm?6/37/6740\">",
"     picture 3",
"    </a>",
"    ). The bladder is closed with two layers of transverse sutures. In our practice, we use a double layer of running 2-0 polyglactin 910 (Vicryl&trade;) sutures. An alternative technique is to perform the initial cystotomy and resect the nodule by cystoscopy, then suture the bladder via conventional or robot-assisted laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For lesions at the vesical base, where the bladder is apposed to the uterus, resection of the underlying myometrium may prevent recurrent symptoms. In a series of 33 women with endometriotic lesions at the bladder base, the recurrence rate was significantly lower in those patients who did versus did not undergo concomitant resection of a 0.5 to 1 cm deep portion of the myometrium contiguous with the endometriotic nodule (7 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the end of the procedure, the bladder is backfilled to confirm that the closure is watertight. Postoperatively, a bladder catheter is left in place for 7 to 10 days to prevent fistula formation. The technique for repairing a cystotomy is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link&amp;anchor=H19#H19\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\", section on 'Bladder injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The removal of bladder endometriosis is contraindicated in pregnant women, including during cesarean section, because the considerable increase in blood flow renders the procedure hemorrhagic. Furthermore, despite shifts in position between the uterus and bladder during gestation, pregnancy status does not facilitate development of vesicouterine cleavage planes due to the firm fibrotic nature of the adhesions associated with endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General complications of laparoscopy or cystoscopy may occur. Potential complications of bladder resection include vesical hematoma and vesicovaginal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link\">",
"     \"Complications of gynecologic laparoscopic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4814325\">",
"    <span class=\"h4\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder endometriosis is rare, and thus the outcome of surgical treatment has been evaluated only in small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/28,38\">",
"     28,38",
"    </a>",
"    ]. The largest series followed 75 women with biopsy-confirmed bladder endometriosis for an average of 60 months following partial cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/40\">",
"     40",
"    </a>",
"    ]. Improvement in symptoms was reported by all patients, with 77 percent reporting excellent improvement. There were no reoperations for bladder lesions. Complications included one vesicovaginal hematoma and one vesicovaginal fistula.",
"   </p>",
"   <p>",
"    In another series, 47 women were followed for an average of 36 months after segmental bladder resection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/38\">",
"     38",
"    </a>",
"    ]. The 14 women with bladder dome lesions remained asymptomatic; for women with bladder base lesions, the rate of recurrence depended upon the extent of the resection, as discussed in the preceding section. (See",
"    <a class=\"local\" href=\"#H4814318\">",
"     'Procedure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390274\">",
"    <span class=\"h1\">",
"     URETERAL ENDOMETRIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral endometriosis may be either intrinsic or extrinsic. Intrinsic endometriosis is defined as the presence of an endometriotic lesion within a thickened ureteric wall, with fibrosis and proliferation of the ureteric muscularis. Rarely, the mucosa may also be involved, with a polypoid tumor-like mass projecting into the lumen. Extrinsic endometriosis is the involvement of overlying peritoneum with extrinsic compression of the ureteric wall [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differentiation between these two forms of ureteral endometriosis has histologic and pathogenetic importance, but has little impact on clinical management since the precise location of the lesion cannot be determined preoperatively. Moreover, both intrinsic and extrinsic forms of the disease may result in ureteral stenosis, as illustrated in one histological study in which severely affected ureters that required resection were affected by intrinsic endometriosis in 52 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical pattern of ureteral endometriosis is consistent with the retrograde menstruation hypothesis of the pathogenesis of deep endometriosis. (See",
"    <a class=\"local\" href=\"#H17036461\">",
"     'Pathogenesis'",
"    </a>",
"    above.). Endometriosis of the ureter is found most frequently on the left side [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This may be because, on the left side, the sigmoid colon prevents the regurgitated endometrial cells from being cleared by the peritoneal circulation. &nbsp;",
"   </p>",
"   <p>",
"    In addition, the most commonly affected portions of the ureter are the distal third, followed by the middle third; involvement of the proximal ureter is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Thus, the most frequent sites of ureteral endometriosis are below the level of tubal efflux. One would expect lesions of the distal ureter to coexist with posterior pouch endometriosis and lesions of the middle third of the ureter to correspond to the level of the ovary. This was illustrated in a series of 96 women with ureteral endometriosis in whom the ipsilateral ovary was involved in more than two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"     43",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17037257\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral endometriosis presents with colicky flank pain in approximately 25 percent of patients and gross hematuria in 15 percent, while up to 50 percent of patients are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/29\">",
"     29",
"    </a>",
"    ]. Due to the lack of symptoms in many women, the diagnosis of this condition is often delayed. As a consequence, ureteral endometriosis can lead to silent loss of renal function.",
"   </p>",
"   <p>",
"    In the absence of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydronephrosis, ureteral endometriosis is generally discovered at the time of laparotomy or laparoscopy for evaluation of pelvic pain or other indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17037264\">",
"    <span class=\"h2\">",
"     Diagnosis and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is typically diagnosed by direct visualization of implants; biopsy and histologic confirmation is the gold standard, as noted above. The diagnosis of ureteral endometriosis is suggested by the finding of hydronephrosis in a patient with known or suspected endometriosis, particularly if symptoms consistent with ureteral involvement are present.",
"   </p>",
"   <p>",
"    The diagnosis of ureteral endometriosis requires a high index of suspicion and is aided by clinicians&rsquo; awareness of the condition. One study of 750 patients with endometriosis who underwent routine renal ultrasound found that 23 (3 percent) had ureterohydronephrosis, 13 (56 percent) of whom were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/48\">",
"     48",
"    </a>",
"    ]. Further study is needed to determine whether routine renal ultrasound should be performed in patients with endometriosis to screen for ureteral endometriosis.",
"   </p>",
"   <p>",
"    The differential diagnosis of ureteral endometriosis includes other conditions that result in hydronephrosis, including stones, malignancy, or lesions that cause external compression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hydronephrosis is typically detected with renal ultrasound. Further radiologic evaluation may be helpful to identify the exact site of the stenosis, thus helping to plan the surgical procedure. Renal imaging findings of renal cortical thinning or decreased kidney size are suggestive of irreversible damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=see_link&amp;anchor=H4#H4\">",
"     \"Radiologic assessment of renal disease\", section on 'Doppler'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal function testing should be performed in women with hydronephrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Assessment of kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17037271\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ureteral endometriosis with hydronephrosis is surgical, since medical therapy has not been proven effective at relieving ureteral obstruction. This is likely because medical treatment does not treat the fibrotic component of endometriotic lesions, which is largely responsible for ureteral obstruction. Relief of obstruction is required to prevent progressive loss of renal function.",
"   </p>",
"   <p>",
"    For selected patients with mild or intermittent hydronephrosis, if surgery is delayed, we suggest a combination of medical therapy and insertion of a ureteral stent. In such cases, close monitoring of renal function is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390281\">",
"    <span class=\"h3\">",
"     Medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral endometriosis is rare, and there are few studies of medical therapy. Case reports of use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    in women with hydronephrosis have not consistently reported relief of obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. The aromatase inhibitor anastrazole was unsuccessful in relieving ureteral obstruction in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390288\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgical treatment of ureteral endometriosis are to remove the endometriotic lesion(s) and relieve ureteral stricture or kinking. Removal of lesions may be difficult to achieve, since endometriotic nodules may infiltrate the ureteral wall and often have no clear cleavage planes in relation to surrounding structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3774465\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of progression of endometriosis is uncertain; thus, it is prudent to remove all endometriotic foci that are close to the ureters to prevent future stenosis and renal damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/54\">",
"     54",
"    </a>",
"    ]. This includes lesions that are found incidentally at time of surgery and are proximal to, but do not directly impinge upon, the ureters.",
"   </p>",
"   <p>",
"    The surgical approach depends upon the extent of the procedure and the surgeon&rsquo;s skills. Ureterolysis is performed by most surgeons laparoscopically; ureteroneocystostomy may require laparotomy.",
"   </p>",
"   <p>",
"    Ureterolysis is the first step of the procedure. The peritoneum overlying the ureter is opened at the level of the pelvic brim, where both the ureter and peritoneum are almost never affected by endometriotic disease or associated fibrosis. The ureter is then isolated down until the level of the cardinal ligament. In the presence of healthy retroperitoneal tissue, this is done by blunt dissection. In the presence of endometriosis, we use the cold or electrosurgical scissors to ablate the lesion, or excise it, if possible.",
"   </p>",
"   <p>",
"    If endometriosis invades the ureteral adventitia (outer layer), more aggressive ureterolysis is necessary. This consists of cutting the adventitial sheath, while leaving the muscular layer intact. During the procedure, unintentional openings of the ureteral lumen can be repaired with two interrupted 4-0 polydioxanone sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/55\">",
"     55",
"    </a>",
"    ]. Of note, however, incisions in the ureteral adventitia may compromise the periureteral vascular supply and increase the risk of postoperative ureteral fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When ureterolysis is complete, the decision is made regarding whether further intervention is required (ureteral stent or resection of a diseased segment). This decision is made based upon visual inspection of the ureter for evidence of compromise of function.",
"   </p>",
"   <p>",
"    Since most lesions are located in the distal ureter, ureteral resection is usually combined with ureteroneocystostomy. The ureter is incised proximal to the stricture and is reimplanted into the bladder. A tension-free anastomosis sometimes requires a bladder-psoas hitch. An anti-reflux plasty of the bladder valve is important in order to avoid ascending infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. When the endometriotic lesion is in the middle or upper third of the ureter, an ureteroureteral anastomosis is preferred.",
"   </p>",
"   <p>",
"    Unfortunately, whether to proceed with resection of an endometriotic segment of the ureter is a subjective decision. Intraoperative visual or other criteria have not been established to predict normal postoperative ureteral function (",
"    <a class=\"graphic graphic_picture graphicRef54395 \" href=\"UTD.htm?3/13/3284\">",
"     picture 4",
"    </a>",
"    ). An attempt to establish such criteria was made in a study of 96 women who underwent surgery for ureteral endometriosis. A visual inspection algorithm was used to decide whether to proceed with expectant management, place a ureteral stent, or perform ureteroneocystostomy. Based upon this protocol, four women had ureteral stent placement (dilated ureter or nondilated ureter that appeared compromised) and two women underwent ureteroneocystostomy (dilated ureter that did not decompress with stenting) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"     43",
"    </a>",
"    ]. Follow-up ranged from 2 to 50 months, during which time ureteral obstruction recurred in only one patient (the patient had undergone ureteroneocystostomy).",
"   </p>",
"   <p>",
"    In our practice, however, in presence of a documented stenosis associated with significant hydronephrosis, we have found that ureteral resection and ureteroneocystostomy rather than aggressive ureterolysis and stenting minimize the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/30,57\">",
"     30,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concomitant ipsilateral oophorectomy is performed in some women when surface ovarian endometriotic lesions or an endometrioma are present. Bilateral oophorectomy is performed in some women to prevent recurrence of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/58\">",
"     58",
"    </a>",
"    ]. Unilateral ligation of the uterine artery might also be required to perform a radical resection of endometriosis involving the parametrium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the treatment of endometriosis\", section on 'Definitive surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with incidentally discovered disease (at time of laparoscopy or laparotomy for other indications), if ureteral adhesions are present, we perform ureterolysis. Many of these patients will not have hydronephrosis (in one series, only 2 of 96 patients with incidentally diagnosed disease had hydronephrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"     43",
"    </a>",
"    ]). If patients require more extensive ureteral surgery (eg, cutting of the ureteral adventitia or ureteral resection), we defer such procedures until informed consent can be obtained.",
"   </p>",
"   <p>",
"    General complications of laparoscopy or laparotomy may occur. Potential complications specific to this procedure include ureteral fistula. In the largest series of 96 women with ureteral endometriosis who underwent ureterolysis and, in two cases, ureteroneocystostomy, complications included one case of septic pelvic thrombophlebitis and one case of position ureteral obstruction following ureteroneocystostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link\">",
"     \"Complications of gynecologic laparoscopic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3774472\">",
"    <span class=\"h4\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 10 case series of women treated for the ureteral endometriosis shows the following rates of recurrence for each type of surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/30,57,59-66\">",
"     30,57,59-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureterolysis alone &ndash; 8 percent (14 of 176)",
"     </li>",
"     <li>",
"      Ureteroneocystostomy &ndash; 3 percent (1 of 39)",
"     </li>",
"     <li>",
"      Ureteroureteral anastomosis &ndash; 11 percent (3 of 28)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few complications were reported. Of note, three ureteral fistulae occurred in patients who underwent ureterolysis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data are limited by the small numbers of patients and the lack of comparative studies. It appears, however, that ureterolysis alone is associated with higher rates of both recurrence and complications compared with ureteroneocystostomy, most likely in cases of moderate or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1993/abstract/55,67\">",
"     55,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"       \"Patient information: Endometriosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       \"Patient information: Endometriosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30390295\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract lesions are found in 1 to 2 percent of women with symptomatic endometriosis. The bladder and ureter are the most common sites of endometriotic lesions of the urinary tract. (See",
"      <a class=\"local\" href=\"#H29778329\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder endometriotic lesions infiltrate the detrusor muscle and may cause nonspecific urinary symptoms that occur during menses, including urinary frequency, urgency, dysuria, or urinary retention. Hematuria is infrequent, but when present, may coincide with menses. Hydronephrosis is found only rarely in women with bladder endometriosis. (See",
"      <a class=\"local\" href=\"#H17036718\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder endometriosis is diagnosed by visualization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy of lesions. Biopsy is necessary to exclude malignancy. This is accomplished most commonly with cystoscopy, but laparoscopy may be necessary in some cases. Bladder endometriosis is often detected by an incidental finding of a bladder wall nodule on pelvic ultrasound. (See",
"      <a class=\"local\" href=\"#H17036780\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women with symptomatic bladder endometriosis, we suggest medical rather than surgical treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgery is reserved for women who have failed or have contraindications to medical therapy, who wish to avoid chronic medical treatment, or who have hydronephrosis. (See",
"      <a class=\"local\" href=\"#H17036840\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy for bladder endometriosis is the same as for other sites of the disease (eg, estrogen-progestin contraceptives, progestins). Surgical treatment entails full thickness resection of the bladder wall at the site of the lesion, with ureteroneocystostomy in some cases. (See",
"      <a class=\"local\" href=\"#H30390260\">",
"       'Medical treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30750173\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral endometriosis may be either within the ureteral wall (intrinsic) or involve the overlying peritoneum (extrinsic). More than half of women with ureteral endometriosis are asymptomatic; some women present with colicky flank pain or gross hematuria. Hydronephrosis in asymptomatic patients may result in silent loss of renal function. (See",
"      <a class=\"local\" href=\"#H30390274\">",
"       'Ureteral endometriosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17037257\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral endometriosis is diagnosed by visualization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy of lesions. Renal ultrasound is performed to detect hydronephrosis and additional testing is generally necessary to evaluate the location of stricture and renal function. (See",
"      <a class=\"local\" href=\"#H17037264\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of ureteral endometriosis with hydronephrosis is surgical, since medical therapy has not been proven effective at relieving ureteral obstruction. For women with mild or intermittent hydronephrosis in whom surgery is delayed, we suggest a combination of medical therapy and insertion of a ureteral stent rather than either treatment alone or no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17037271\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureterolysis is performed in all women who undergo surgical treatment of ureteral endometriosis. Subsequent surgical management depends upon visual inspection of the ureter (eg, dilation, dusk appearance). Stent placement or resection of a segment of the ureter may be required. (See",
"      <a class=\"local\" href=\"#H3774465\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/1\">",
"      STANLEY KE Jr, UTZ DC, DOCKERTY MB. CLINICALLY SIGNIFICANT ENDOMETRIOSIS OF THE URINARY TRACT. Surg Gynecol Obstet 1965; 120:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/2\">",
"      Donnez J, Spada F, Squifflet J, Nisolle M. Bladder endometriosis must be considered as bladder adenomyosis. Fertil Steril 2000; 74:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/3\">",
"      Fedele L, Piazzola E, Raffaelli R, Bianchi S. Bladder endometriosis: deep infiltrating endometriosis or adenomyosis? Fertil Steril 1998; 69:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/4\">",
"      Buka NJ. Vesical endometriosis after cesarean section. Am J Obstet Gynecol 1988; 158:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/5\">",
"      Cruz Guerra NA, Linares Quevedo A, Cuesta Roca C, et al. [Bladder endometriosis in a patient with cesarean history]. Arch Esp Urol 2002; 55:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/6\">",
"      Vercellini P, Frontino G, Pisacreta A, et al. The pathogenesis of bladder detrusor endometriosis. Am J Obstet Gynecol 2002; 187:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/7\">",
"      De Cicco C, Corona R, Schonman R, et al. Bowel resection for deep endometriosis: a systematic review. BJOG 2011; 118:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/8\">",
"      Vercellini P, Aimi G, De Giorgi O, et al. Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet Gynaecol 1998; 105:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/9\">",
"      Vercellini P, Busacca M, Aimi G, et al. Lateral distribution of recurrent ovarian endometriotic cysts. Fertil Steril 2002; 77:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/10\">",
"      Somigliana E, Vercellini P, Gattei U, et al. Bladder endometriosis: getting closer and closer to the unifying metastatic hypothesis. Fertil Steril 2007; 87:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/11\">",
"      Bricou A, Batt RE, Chapron C. Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right. Eur J Obstet Gynecol Reprod Biol 2008; 138:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/12\">",
"      Chapron C, Chopin N, Borghese B, et al. Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod 2006; 21:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/13\">",
"      Vercellini P, Frontino G, Pietropaolo G, et al. Deep endometriosis: definition, pathogenesis, and clinical management. J Am Assoc Gynecol Laparosc 2004; 11:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/14\">",
"      STANLEY KE Jr, UTZ DC, DOCKERTY MB. CLINICALLY SIGNIFICANT ENDOMETRIOSIS OF THE URINARY TRACT. Surg Gynecol Obstet 1965; 120:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/15\">",
"      Sangi-Haghpeykar H, Poindexter AN 3rd. Epidemiology of endometriosis among parous women. Obstet Gynecol 1995; 85:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/16\">",
"      Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med 1982; 27:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/17\">",
"      Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/18\">",
"      ABESHOUSE BS, ABESHOUSE G. Endometriosis of the urinary tract: a review of the literature and a report of four cases of vesical endometriosis. J Int Coll Surg 1960; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/19\">",
"      Yohannes P. Ureteral endometriosis. J Urol 2003; 170:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/20\">",
"      Kovoor E, Nassif J, Miranda-Mendoza I, Wattiez A. Endometriosis of bladder: outcomes after laparoscopic surgery. J Minim Invasive Gynecol 2010; 17:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/21\">",
"      Westney OL, Amundsen CL, McGuire EJ. Bladder endometriosis: conservative management. J Urol 2000; 163:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/22\">",
"      Abrao MS, Dias JA Jr, Bellelis P, et al. Endometriosis of the ureter and bladder are not associated diseases. Fertil Steril 2009; 91:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/23\">",
"      Goncalves MO, Dias JA Jr, Podgaec S, et al. Transvaginal ultrasound for diagnosis of deeply infiltrating endometriosis. Int J Gynaecol Obstet 2009; 104:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/24\">",
"      Chami&eacute; LP, Blasbalg R, Gon&ccedil;alves MO, et al. Accuracy of magnetic resonance imaging for diagnosis and preoperative assessment of deeply infiltrating endometriosis. Int J Gynaecol Obstet 2009; 106:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/25\">",
"      Grasso RF, Di Giacomo V, Sedati P, et al. Diagnosis of deep infiltrating endometriosis: accuracy of magnetic resonance imaging and transvaginal 3D ultrasonography. Abdom Imaging 2010; 35:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/26\">",
"      Busard MP, Mijatovic V, van Kuijk C, et al. Magnetic resonance imaging in the evaluation of (deep infiltrating) endometriosis: the value of diffusion-weighted imaging. J Magn Reson Imaging 2010; 32:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/27\">",
"      Fedele L, Bianchi S, Montefusco S, et al. A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis. Fertil Steril 2008; 90:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/28\">",
"      Chapron C, Dubuisson JB. Laparoscopic management of bladder endometriosis. Acta Obstet Gynecol Scand 1999; 78:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/29\">",
"      Comiter CV. Endometriosis of the urinary tract. Urol Clin North Am 2002; 29:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/30\">",
"      Antonelli A, Simeone C, Zani D, et al. Clinical aspects and surgical treatment of urinary tract endometriosis: our experience with 31 cases. Eur Urol 2006; 49:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/31\">",
"      Nezhat CH, Malik S, Osias J, et al. Laparoscopic management of 15 patients with infiltrating endometriosis of the bladder and a case of primary intravesical endometrioid adenosarcoma. Fertil Steril 2002; 78:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/32\">",
"      Pastor-Navarro H, Gim&eacute;nez-Bachs JM, Donate-Moreno MJ, et al. Update on the diagnosis and treatment of bladder endometriosis. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/33\">",
"      Lousquy R, Borghese B, Chapron C. [Deep bladder endometriosis: how do I...to perform a laparoscopic partial cystectomy?]. Gynecol Obstet Fertil 2010; 38:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/34\">",
"      Seracchioli R, Mannini D, Colombo FM, et al. Cystoscopy-assisted laparoscopic resection of extramucosal bladder endometriosis. J Endourol 2002; 16:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/35\">",
"      Sener A, Chew BH, Duvdevani M, et al. Combined transurethral and laparoscopic partial cystectomy and robot-assisted bladder repair for the treatment of bladder endometrioma. J Minim Invasive Gynecol 2006; 13:245.",
"     </a>",
"    </li>",
"    <li>",
"     Pang, ST, Chao, A, Wang, CJ, et al. Transurethral partial cystectomy and laparoscopic reconstruction for the management of bladder endometriosis. Fertil Steril 2008; 90:2014.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/37\">",
"      Nerli RB, Reddy M, Koura AC, et al. Cystoscopy-assisted laparoscopic partial cystectomy. J Endourol 2008; 22:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/38\">",
"      Fedele L, Bianchi S, Zanconato G, et al. Long-term follow-up after conservative surgery for bladder endometriosis. Fertil Steril 2005; 83:1729.",
"     </a>",
"    </li>",
"    <li>",
"     Vercellini, P, Aimi, G, Amicarelli, F et al. Treatment of endometriosis associated with pain. In: Reconstructive and Reproductive Surgery in Gynecology, Gomel &amp; Brill, (Eds), Informa Healtcare, London, in press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/40\">",
"      Chapron C, Bourret A, Chopin N, et al. Surgery for bladder endometriosis: long-term results and concomitant management of associated posterior deep lesions. Hum Reprod 2010; 25:884.",
"     </a>",
"    </li>",
"    <li>",
"     Clement, PB. Endometriosis, lesions of the secondary Mullerian system, and pelvic mesothelial proliferations. In: Blaustein's pathology of the female genital tract, 3rd ed, Kurman RJ (Ed), Springer-Verlag, New York 1989. p.516.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/42\">",
"      Chapron C, Chiodo I, Leconte M, et al. Severe ureteral endometriosis: the intrinsic type is not so rare after complete surgical exeresis of deep endometriotic lesions. Fertil Steril 2010; 93:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/43\">",
"      Bosev D, Nicoll LM, Bhagan L, et al. Laparoscopic management of ureteral endometriosis: the Stanford University hospital experience with 96 consecutive cases. J Urol 2009; 182:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/44\">",
"      Vercellini P, Pisacreta A, Pesole A, et al. Is ureteral endometriosis an asymmetric disease? BJOG 2000; 107:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/45\">",
"      Antonelli A, Simeone C, Frego E, et al. Surgical treatment of ureteral obstruction from endometriosis: our experience with thirteen cases. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/46\">",
"      Zanetta G, Webb MJ, Segura JW. Ureteral endometriosis diagnosed at ureteroscopy. Obstet Gynecol 1998; 91:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/47\">",
"      Gagnon RF, Arsenault D, Pichette V, Tanguay S. Acute renal failure in a young woman with endometriosis. Nephrol Dial Transplant 2001; 16:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/48\">",
"      Carmignani L, Vercellini P, Spinelli M, et al. Pelvic endometriosis and hydroureteronephrosis. Fertil Steril 2010; 93:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/49\">",
"      Gardner B, Whitaker RH. The use of danazol for ureteral obstruction caused by endometriosis. J Urol 1981; 125:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/50\">",
"      Jepsen JM, Hansen KB. Danazol in the treatment of ureteral endometriosis. J Urol 1988; 139:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/51\">",
"      Rivlin ME, Krueger RP, Wiser WL. Danazol in the management of ureteral obstruction secondary to endometriosis. Fertil Steril 1985; 44:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/52\">",
"      Matsuura K, Kawasaki N, Oka M, et al. Treatment with danazol of ureteral obstruction caused by endometriosis. Acta Obstet Gynecol Scand 1985; 64:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/53\">",
"      Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008; 90:2004.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/54\">",
"      Fedele L, Bianchi S, Zanconato G, et al. Is rectovaginal endometriosis a progressive disease? Am J Obstet Gynecol 2004; 191:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/55\">",
"      Scioscia M, Molon A, Grosso G, Minelli L. Laparoscopic management of ureteral endometriosis. Curr Opin Obstet Gynecol 2009; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/56\">",
"      Ahn M, Loughlin KR. Psoas hitch ureteral reimplantation in adults--analysis of a modified technique and timing of repair. Urology 2001; 58:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/57\">",
"      Carmignani L, Ronchetti A, Amicarelli F, et al. Bladder psoas hitch in hydronephrosis due to pelvic endometriosis: outcome of urodynamic parameters. Fertil Steril 2009; 92:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/58\">",
"      Kane C, Drouin P. Obstructive uropathy associated with endometriosis. Am J Obstet Gynecol 1985; 151:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/59\">",
"      Donnez J, Nisolle M, Squifflet J. Ureteral endometriosis: a complication of rectovaginal endometriotic (adenomyotic) nodules. Fertil Steril 2002; 77:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/60\">",
"      Ghezzi F, Cromi A, Bergamini V, et al. Outcome of laparoscopic ureterolysis for ureteral endometriosis. Fertil Steril 2006; 86:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/61\">",
"      Mereu L, Gagliardi ML, Clarizia R, et al. Laparoscopic management of ureteral endometriosis in case of moderate-severe hydroureteronephrosis. Fertil Steril 2010; 93:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/62\">",
"      Seracchioli R, Mabrouk M, Manuzzi L, et al. Importance of retroperitoneal ureteric evaluation in cases of deep infiltrating endometriosis. J Minim Invasive Gynecol 2008; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/63\">",
"      Nezhat C, Nezhat F, Nezhat CH, et al. Urinary tract endometriosis treated by laparoscopy. Fertil Steril 1996; 66:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/64\">",
"      Frenna V, Santos L, Ohana E, et al. Laparoscopic management of ureteral endometriosis: our experience. J Minim Invasive Gynecol 2007; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/65\">",
"      Schneider A, Touloupidis S, Papatsoris AG, et al. Endometriosis of the urinary tract in women of reproductive age. Int J Urol 2006; 13:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/66\">",
"      P&eacute;rez-Utrilla P&eacute;rez M, Aguilera Baz&aacute;n A, Alonso Dorrego JM, et al. Urinary tract endometriosis: clinical, diagnostic, and therapeutic aspects. Urology 2009; 73:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1993/abstract/67\">",
"      Berlanda N, Vercellini P, Carmignani L, et al. Ureteral and vesical endometriosis. Two different clinical entities sharing the same pathogenesis. Obstet Gynecol Surv 2009; 64:830.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14190 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-3D5B54884C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1993=[""].join("\n");
var outline_f1_60_1993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30390295\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30390246\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17036461\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29778329\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30390253\">",
"      BLADDER ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17036718\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17036780\">",
"      Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17036840\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30390260\">",
"      - Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30750173\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4814318\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4814325\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30390274\">",
"      URETERAL ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17037257\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17037264\">",
"      Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17037271\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30390281\">",
"      - Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30390288\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3774465\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3774472\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30390295\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14190|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/21/17759\" title=\"picture 1\">",
"      Bladder endometriosis on cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17905\" title=\"picture 2\">",
"      Bladder endometriosis with anterior adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/37/6740\" title=\"picture 3\">",
"      Bladder endometriosis resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/13/3284\" title=\"picture 4\">",
"      Ureteral endometriosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=related_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=related_link\">",
"      Radiologic assessment of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24858?source=related_link\">",
"      Rectovaginal or bowel endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14056?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_60_1994="Overview of angiogenesis inhibitors";
var content_f1_60_1994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of angiogenesis inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Calvin J Kuo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/60/1994/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/60/1994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the embryo develops, mesodermal precursors differentiate into endothelial cells and assemble into primitive vascular networks in a process called vasculogenesis. These networks undergo extensive budding and branching, and associate themselves with vascular smooth muscle elements in a process termed angiogenesis, thus yielding an extensive vasculature capable of responding to systemic as well as local tissue needs. The end result is that each cell is supported by a capillary network that enables it to receive necessary nutrients and oxygen, and export its cellular products (eg, hormones, vasoactive materials, metabolic waste products).",
"   </p>",
"   <p>",
"    Following embryogenesis, angiogenesis is repeated during tissue repair (eg, wound healing) and overall growth of the organism. Angiogenesis also occurs during certain specialized situations such as during the menstrual cycle and implantation of the embryo during pregnancy, and can be highly coordinated with hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/1\">",
"     1",
"    </a>",
"    ]. Alterations in normal or newly formed vascular networks can also be associated with disease, as illustrated by the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occlusion of blood vessels can result in tissue hypoxia and damage (eg, peripheral vascular disease, myocardial infarction, stroke, vasoocclusion in sickle cell disease).",
"     </li>",
"     <li>",
"      Interference with the action of vascular endothelial growth factor and placental growth factor may play a central role in the placental hypoperfusion seen in preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis of preeclampsia\", section on 'Systemic endothelial dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inappropriate and excessive growth of blood vessels plays a causative role in ocular disorders such as diabetic retinopathy and macular degeneration.",
"     </li>",
"     <li>",
"      The induction of angiogenesis (neovascularization) is an important mechanism by which tumors promote their own continued growth and metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the central role of angiogenesis in tumor growth, it represents an attractive therapeutic target for patients with cancer. The general approaches for inhibiting angiogenesis in the treatment of malignancy will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The toxicity of anti-angiogenic drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical uses of angiogenesis inhibitors are discussed in the relevant disease topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF ANGIOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiogenesis is a complex process under both positive and negative control by naturally-occurring growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Many, but not all of the growth factors that stimulate angiogenesis bind",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . The biologic counterpart of this property is the ability to bind to structurally similar glycosaminoglycans known as heparan sulfates on cell surfaces and the extracellular matrix (ECM). Binding of a growth factor to heparan sulfate typically stabilizes the growth factor, prolongs its tissue half-life, and may facilitate its binding to specific high affinity receptors.",
"   </p>",
"   <p>",
"    Growth factors are a broad category of endogenous molecules that promote cell proliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    differentiation. All growth factors that induce neovascularization are presumed to do so by stimulation of endothelial cell proliferation and migration. Other contributory factors include stimulation of ECM breakdown, attraction of pericytes and macrophages, stimulation of smooth muscle cell proliferation and migration, formation and \"sealing\" of new vascular structures, and deposition of new matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability of growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) system, and transcription factors such as hypoxia inducible factor (HIF-1) to increase the rate of endothelial cell proliferation has been demonstrated in several animal models; proliferation is largely limited to ischemic zones, even following systemic administration or activation of these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. The mechanism that limits their action to ischemic areas is not clear, but it may involve spatially limited expression of high affinity growth factor receptors, a local interplay of growth factors and ECM-derived angiogenic inhibitors, and the presence or absence of other regulatory molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiopoietins are a subset of growth factors identified for their role in angiogenesis. Specific angiopoietins (eg, angiopoietin-1) appear to regulate endothelial cell survival as well as interactions with supporting pericytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the capacity of tissues to respond to angiogenic signaling may be regulated by changes in the composition of the ECM, including expression of matrix-digesting enzymes such as matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/17\">",
"     17",
"    </a>",
"    ]. Changes in endothelial cell expression of integral matrix proteins (eg, avb3 and avb5 integrins) and heparan sulfate-carrying proteoglycans (such as syndecans) may also be important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The existence of both positive and negative angiogenesis regulators has led to two separate strategies for inhibiting pathologic angiogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of positively-acting agents (eg, small molecule VEGF receptor [VEGFR] inhibitors, antibodies directed against VEGF, VEGFR, or endothelial cell surface proteins, and inhibitors of angiopoietin pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Anti-VEGF neutralizing antibodies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of negatively-acting agents or functionally-related analogs (eg, angiostatin, endostatin, fumagillin, matrix metalloproteinase inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/21\">",
"       21",
"      </a>",
"      ]). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Other antiangiogenesis approaches'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASCULAR ENDOTHELIAL GROWTH FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dominant growth factor controlling angiogenesis is vascular endothelial growth factor (VEGF, previously called vascular permeability factor [VPF]) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The VEGF family is comprised of six different proteins encoded by distinct genes, namely VEGF-A, VEGF-B, VEGF-C, VEGF-D, orf virus VEGF (VEGF-E), and placental growth factor (PlGF).",
"   </p>",
"   <p>",
"    VEGF, produced by a number of different cell types (eg, endothelial cells, platelets), acts selectively on vascular endothelial cells, and is capable of stimulating angiogenesis in vitro and in vivo. As such, it appears to play an active role in the induction, maintenance, and growth of vascular endothelial cells. Because of its association with both normal and abnormal angiogenesis, VEGF has become an attractive target for both proangiogenic and antiangiogenic therapy. Direct actions of VEGF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stimulation of endothelial mitogenesis",
"     </li>",
"     <li>",
"      Promotion of endothelial survival by an Akt-dependent pathway",
"     </li>",
"     <li>",
"      Control of vascular permeability; VEGF is 50,000 times more potent in inducing vascular leakage than histamine [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/25\">",
"       25",
"      </a>",
"      ]. The mechanism of this effect appears to be fenestration of the endothelium of small venules and capillaries through a Src kinase-dependent mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased expression of tissue plasminogen activator, urokinase plasminogen activator, collagenases, and matrix metalloproteinases. All are involved in the degradation of the ECM, needed for endothelial cell migration [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/27-31\">",
"       27-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In embryos lacking one of the two VEGF alleles, the mutation is lethal by early gestation. Angiogenesis and blood-island formation are impaired, resulting in several developmental anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regulation of adult erythropoiesis and synthesis of erythropoietin; inhibition of VEGF induce hepatic expression of erythropoietin through VEGF-dependent endothelial-hepatocyte cross-talk [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of hypoxia and cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression of VEGF is highly regulated by hypoxia, providing a feedback mechanism to accommodate reduced tissue oxygenation via the promotion of new blood vessel formation. The regulation of VEGF expression by hypoxia is mediated by a family of hypoxia-inducible transcription factors (HIFs), which increase transcription of the VEGF gene [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. In addition, hypoxia also upregulates VEGF levels by stabilizing VEGF messenger RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/38\">",
"     38",
"    </a>",
"    ], as well as through multiple mechanisms not involving HIF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H19#H19\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia-inducible factor and the response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytokines such as epidermal growth factor (EGF) and transforming growth factor beta (TGF-beta) and other influences (eg, p53 expression) may also increase VEGF expression by a number of different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Conversely, the antiangiogenic (and antitumor) properties of interferon alfa may be mediated, at least in part, by inhibition of VEGF gene transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     VEGF gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VEGF protein family consists of a number of different isoforms encoded by splice variants of a single gene containing 8 exons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/48\">",
"     48",
"    </a>",
"    ]. The biological activity, expression patterns, and binding to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and extracellular matrix isoforms differ considerably among these isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/49\">",
"     49",
"    </a>",
"    ]. The smaller VEGF isoforms are secreted in a soluble form, whereas the larger ones remain cell-bound. Bioavailability of the larger isoforms is regulated by proteolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic variability in the promoter regions of VEGF affects the activity and expression of the VEGF protein, and may also affect the benefit of VEGF inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     VEGF receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEGFs mediate angiogenic signals to the vascular endothelium via high affinity receptor tyrosine kinases, designated VEGFR-1 (Flt1), VEGFR-2",
"    <span class=\"nowrap\">",
"     (Flk1/KDR),",
"    </span>",
"    and VEGFR-3 (Flt4). These receptors, which are expressed almost exclusively on endothelial cells, are characterized by seven immunoglobulin-like domains in their extracellular region, a single transmembrane domain, and an intracellular tyrosine kinase domain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropilin-1, a cell surface glycoprotein originally implicated as a semaphorin receptor controlling developmental axon guidance, also functions as a nonclassical VEGF receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/52\">",
"     52",
"    </a>",
"    ]. It binds to exon 7 of the splice variant VEGF",
"    <sub>",
"     165",
"    </sub>",
"    as opposed to the more N-terminal motifs of VEGF recognized by the classical VEGF receptors Flk1 and Flt1. Neuropilin-1 has been proposed to function as a co-receptor for VEGFR-2 capable of enhancing the biological effect of VEGF",
"    <sub>",
"     165",
"    </sub>",
"    on endothelial cells; a related receptor, Neuropilin-2, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H946882\">",
"    <span class=\"h2\">",
"     Differential expression of VEGF receptors on tip cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;A heterogeneity exists among endothelial cell populations, in which the cell at the leading edge of an angiogenic sprout (\"endothelial tip cell\") is both phenotypically and functionally distinct from the remainder of the trailing endothelium comprising the remainder of the sprout (\"stalk cells\"). Tip cells are primarily responsible for sensing chemo-attractive VEGF gradients secreted by hypoxic tissue. Moreover, tip cells express high levels of VEGFR3 and",
"    <strong>",
"     D",
"    </strong>",
"    e",
"    <strong>",
"     L",
"    </strong>",
"    ta-",
"    <strong>",
"     L",
"    </strong>",
"    like 4 (DLL4), while the stalk cells express high levels of Jagged and Notch, with paracrine signaling between tip and stalk cells reinforcing these phenotypic differences [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Conceivably, pharmacologic inhibition directed solely against tip cells could offer highly selective anti-angiogenic benefits. (See",
"    <a class=\"local\" href=\"#H946996\">",
"     'Delta-like 4/Jagged Notch'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     VEGF in malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEGF action likely underlies the highly permeable and haphazard architecture of tumor vasculature relative to normal capillaries. VEGF mRNA and protein are markedly upregulated in the vast majority of human tumors. VEGF in tumors can be produced by tumor cells, stroma, and endothelial cells, consistent with autocrine and paracrine modes of action [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In some tumors, VEGF overexpression is associated with poor prognosis and reduced survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis and biology of malignant gliomas\", section on 'Molecular biology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Receptors for VEGF (VEGFRs) are expressed on tumor cells, and VEGFR-2 is upregulated in tumor endothelium. This pleiotropic expression may contribute to cross-talk of VEGF signalling in tumors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTI-ANGIOGENIC THERAPY OF CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     The angiogenic switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiogenesis is a rate-limiting step for numerous pathologic processes, including cancer growth [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/25\">",
"     25",
"    </a>",
"    ]. The concept of an \"angiogenic switch\" has been proposed, whereby, as the tumor grows and cells in the center of the tumor become hypoxic, the tumor initiates recruitment of its own blood supply, by shifting the balance between angiogenesis inhibitors and stimulators towards the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Thus, neovascularization both precedes and is necessary for tumor progression and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanistically, the development of tumor blood vasculature is complex, involving the growth of blood vessels into initially avascular tumor masses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/27-30\">",
"     27-30",
"    </a>",
"    ], early co-option of vasculature from neighboring tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/62\">",
"     62",
"    </a>",
"    ], as well as a contribution from circulating endothelial stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Given the therapeutic potential of angiogenesis blockade, significant efforts have been devoted towards understanding the molecular mechanisms underlying these events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that cancer growth is angiogenesis-dependent has been repeatedly affirmed by experimental treatment of tumors with angiogenesis inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Striking inhibition of tumor growth in experimental animals can be achieved by selective inhibition of VEGF via anti-VEGF monoclonal antibodies (MoAbs), VEGF receptor small molecule kinase inhibitors or MoAbs, or soluble VEGF receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/71-75\">",
"       71-75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An alternative approach is to inhibit one or more of the molecules that stimulate VEGF expression (eg, EGF and its receptor, platelet-derived growth factor [PDGF] and its receptor, HIFs, cyclooxygenase-2 [COX-2] inhibitors, and IL-1beta) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/76-80\">",
"       76-80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of endogenous inhibitors of angiogenesis (eg, endostatin, angiostatin) has also shown efficacy in xenograft models [",
"      <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/81-83\">",
"       81-83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these strategies have resulted in inhibition of a wide variety of diverse tumor types, consistent with the concept that tumor growth may be angiogenesis-dependent, regardless of the tissue of origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanisms for clinical effects of VEGF inhibition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Inhibition of tumor endothelial proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, the anti-tumor effects of VEGF inhibition have been ascribed to the observed reductions in tumor microvessel density and tumor blood flow. VEGF blockade as monotherapy has been clearly shown to have a direct and rapid antivascular effect in both animal and human tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/84\">",
"     84",
"    </a>",
"    ], presumably through deprivation of tumor vascular supply and inhibition of endothelial proliferation.",
"   </p>",
"   <p>",
"    In an animal tumor model, inhibition of VEGF receptor signaling caused a loss of 50 to 60 percent of tumor vasculature, although empty sleeves of basement membrane and pericytes were left behind [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/85\">",
"     85",
"    </a>",
"    ]. By seven days after drug withdrawal, the tumors were again fully vascularized. These results suggest that the empty sleeves of basement membrane and accompanying pericytes can provide a scaffold for rapid regrowth of tumor vasculature after removal of anti-VEGF therapy they also highlight the importance of pericytes and basement membrane components as potential additional targets. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Vascular disrupting agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, in a retrospective analysis of five randomized, placebo-controlled phase III trials in patients receiving the VEGF-blocking monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for breast, colorectal, renal, or pancreatic cancer, similar patterns of disease progression and mortality rates were seen following discontinuation of bevacizumab or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vascular normalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative hypothesis for the anti-tumor effects of VEGF has emerged with the observation that, with the notable exception of renal cell carcinoma,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    appears more efficacious in concert with chemotherapy than as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/87\">",
"     87",
"    </a>",
"    ]. It has been proposed that VEGF blockade results in a temporary and paradoxical \"normalization\" of tumor vasculature, with selective pruning of poorly formed vessels and a resulting temporary improvement of blood flow and oxygen delivery to the tumor, which in turn enhances chemotherapy delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of VEGF and its activity as a vascular permeability factor is postulated to reduce vessel leakiness and thus tumor interstitial pressure. The net effect of improved tumor blood flow and reduced tumor interstitial pressure is enhanced delivery of chemotherapeutic agents to the tumor cells. It is possible that this mechanism predominates at intermediate levels of VEGF inhibition, while more classical anti-angiogenic mechanisms may predominate at higher levels of VEGF inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reduction of edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;In brain tumors such as glioblastoma, vessel leak with subsequent edema can elevate intracranial pressures to dangerous levels, causing damage to the brain by herniation and significantly increasing patient mortality. Treatment of brain tumors with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    clearly reduces vascular leak and edema in patients with glioblastoma, as indicated by strong reductions in the extravasated gadolinium signal on MRI, which can be accompanied by improved neurologic status. Such MRI findings actually overestimate the reduction in tumor vascularity from VEGF inhibitors, since comparatively smaller reductions in vascular content are measured when larger intravascular tracers such as iron-based nanoparticles are used for imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potential resistance to anti-angiogenic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of angiogenesis inhibitors to cytotoxic chemotherapy often does not prolong survival of cancer patients for more than a few months, presumably because the tumors elicit evasive resistance or adaptation to these agents. Preclinical data have raised the possibility that angiogenesis inhibitors might in fact reduce primary tumor growth while at the same time inducing tumor adaptation, invasiveness and metastatic behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. These findings may help to explain the development of resistance to these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/94\">",
"     94",
"    </a>",
"    ], but their relevance to clinical use of angiogenesis inhibitors in patients with cancer is as yet unknown. Tumor production of alternative angiogenic factors, such as FGF and HGF, may help underlie clinical resistance to VEGF inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biomarkers of angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The search for biomarkers of angiogenesis and antiangiogenesis and their successful use in the development of angiogenesis inhibitor therapy is an ongoing challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. However, no validated biomarkers are currently available for routine clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ANTI-VEGF NEUTRALIZING ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies have been employed to target VEGF signaling in patients with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/98\">",
"     98",
"    </a>",
"    ]. The most information is available on the anti-VEGF monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a humanized monoclonal antibody directed against VEGF that recognizes all isoforms of VEGF-A. A notable property is its extremely long circulating half-life of 17 to 21 days after IV infusion, which easily exceeds that of small molecule VEGF inhibitors. Bevacizumab is taken up by platelets in patients receiving this agent, resulting in virtually complete neutralization of platelet VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on its efficacy in advanced colorectal cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    became the first angiogenesis inhibitor approved for treatment of cancer in the United States. Encouraging results have also emerged from clinical trials in other solid tumors. However, biomarkers that reliably predict for the clinical efficacy of this agent in cancer patients have not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is associated with several toxicities, some serious. Most of these are related to its effects on the systemic (ie, non-tumor) vasculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SMALL MOLECULE TYROSINE KINASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, small molecule tyrosine kinase inhibitors (TKIs) have demonstrated promising antitumor activity in a variety of malignancies. Unlike monoclonal antibodies, TKIs have the advantage of oral bioavailability. They are also characterized by somewhat promiscuous activity (ie, not confined to VEGF receptors), inhibiting other tyrosine receptors and tyrosine kinases involved in tumor growth and angiogenesis. Examples of other tyrosine kinases inhibited by the antiangiogenic TKIs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet derived growth factor receptor (PDGFR); PDGF has been implicated in the regulation of endothelial-pericyte interactions",
"     </li>",
"     <li>",
"      c-kit receptor; c-kit signaling can influence cell survival, proliferation, and migration",
"     </li>",
"     <li>",
"      Epidermal growth factor receptor (EGFR); EGF has angiogenic and mitogenic activity",
"     </li>",
"     <li>",
"      Fibroblast growth factor receptor (FGFR); FGF has potent mitogenic activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The broader specificity of TKIs is attributable to the structural similarity of the catalytic ATP-binding site region amongst the tyrosine kinase superfamily. Given that target specificity is not limited to VEGF receptor tyrosine kinases, these are also referred to as multitargeted tyrosine kinase inhibitors or antiangiogenic TKIs.",
"   </p>",
"   <p>",
"    Such broad-spectrum activity may in fact enhance the action of these compounds relative to monoclonal antibodies, allowing the simultaneous inhibition of multiple signaling pathways contributing to tumor angiogenesis and tumor growth, both within the tumor vasculature and the tumor mass itself. Research to determine these additional mechanisms of TKI effect on tumors is ongoing.",
"   </p>",
"   <p>",
"    Examples of some of the antiangiogenic TKIs in clinical use and the receptor tyrosine kinases they target include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       Sorafenib",
"      </a>",
"      inhibits VEGFR2, fms-like tyrosine kinase 3 (FLT3), PDGFR, and fibroblast growth factor receptor (FGFR)-1.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       Sunitinib",
"      </a>",
"      targets numerous receptors including c-kit, VEGFR1-3, PDGFRa, PDGFRb, FLT3, CSF-1R, and REarranged during Transfection (RET).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       Pazopanib",
"      </a>",
"      targets VEGFR1-3, PDGFR alpha and beta, FGFR1 and 3, c-kit, and other tyrosine kinases.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       Axitinib",
"      </a>",
"      is a selective VEGFR inhibitor that targets VEGFR1-3.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"       Vandetanib",
"      </a>",
"      targets VEGFR, RET, and EGFR.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=see_link\">",
"       Regorafenib",
"      </a>",
"      targets VEGFR1-3 in addition to RET, c-kit, PDGFRa and b, FGFR1 and 2, and other membrane-bound and intracellular kinases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative disadvantages of the small molecule TKIs include somewhat short circulating half-lives requiring daily dosing, relatively low target affinity compared with monoclonal antibodies, and side effect profiles that may reflect the promiscuity of action amongst multiple kinases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H946928\">",
"    <span class=\"h1\">",
"     SOLUBLE VEGF &ldquo;DECOY&rdquo; RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soluble &ldquo;decoy&rdquo; receptors comprised of native VEGFR sequences can bind to VEGF and prevent its interaction with VEGFRs on tumor or endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    is an intravenously administered recombinant fusion protein that contains the VEGF-binding domains of VEGFR1 and VEGFR2 fused to the Fc domain of human IgG1, and functions as a soluble decoy receptor for VEGF. Aflibercept inactivates multiple members of the VEGF family including VEGF-A, VEGF-B, and PlGF by preventing binding to their receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/62\">",
"     62",
"    </a>",
"    ]. Aflibercept has potentially higher affinity for VEGF-A when compared with anti-VEGF monoclonal antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OTHER ANTIANGIOGENESIS APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117146104\">",
"    <span class=\"h2\">",
"     EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermal growth factor (EGF) proteins promote cell proliferation and differentiation by binding to the EGF receptor (EGFR), a tyrosine kinase receptor present on many cell types. EGFR (also called HER1 and ERBB1) is related to other receptor tyrosine kinases of the ERBB family.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    are orally-active small molecule tyrosine kinase inhibitors that inhibit the tyrosine kinase domain of the EGFR and have antitumor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/44,103\">",
"     44,103",
"    </a>",
"    ]. Their antitumor effects may be mediated, in part, by inhibition of tumor angiogenesis, as well as via reduced production of proangiogenic factors (eg, VEGF) by tumor cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117146124\">",
"    <span class=\"h2\">",
"     Imunomodulatory drugs (IMiDs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally marketed as a sedative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    was taken off the market because of severe teratogenicity. However, thalidomide was subsequently shown to exhibit clinical activity in several malignant disorders that have been linked to abnormal angiogenesis. Thalidomide has been shown to inhibit FGF-dependent angiogenesis in vivo, but additionally exhibits potent immunomodulatory effects. Analogs of thalidomide (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    ), also called immunomodulatory drugs (IMiDs) were synthesized by modifying the original thalidomide structure. The activity of the IMiDs appears to depend on cerebron, a protein component of the ubiquitin proteasome pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H946989\">",
"    <span class=\"h2\">",
"     Inhibition of hypoxia-inducible factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypoxia-inducible factors (HIFs) are hypoxia-regulated transcription factors that under normoxic conditions undergo rapid degradation via prolyl hydroxylase-dependent hydroxylation, followed by ubiquitination and degradation. However, in hypoxic tissues such as tumors, this hydroxylation does not occur, allowing HIF stabilization and expression of target genes such as VEGF and erythropoietin (EPO). HIF inhibition has thus been proposed as a novel strategy for anti-angiogenic therapy by which expression of VEGF and other angiogenic signals could be interrupted [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although HIF stabilization (ie, HIF stimulation) is achievable with small molecule prolyl hydroxylase inhibitors, the opposing process of HIF inhibition has proven relatively intractable to manipulation by conventional pharmacologic means. EZN-2968, a locked nucleic acid antisense oligonucleotide targeting the HIF-1a transcript, is under clinical investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, animal models predict that specific inhibition of a prolyl hydroxylase could induce an HIF stabilization that could paradoxically normalize the endothelial lining and induce vessel maturation, resulting in improved tumor perfusion and oxygenation with inhibition of tumor cell invasion, intravasation, and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H946996\">",
"    <span class=\"h2\">",
"     Delta-like 4/Jagged Notch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Notch proteins are large transmembrane receptors that interact with Jagged and Delta-like ligands that are themselves transmembrane proteins. Intriguingly, the action of the transmembrane receptor Delta-like 4 (DLL4) via its interaction with ligands of the Notch family appears to regulate angiogenesis. Embryonic deletion of one copy of the Delta-like 4 locus results in embryonic lethality in the heterozygous state from vascular defects.",
"   </p>",
"   <p>",
"    Pharmacologic inhibition of DLL4 during postnatal retinal angiogenesis or tumor angiogenesis is accompanied by marked vascular hyperproliferation. Paradoxically, these excessive blood vessels are not patent, producing a decrease in perfusion overall and a net anti-angiogenic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Vascular hyperproliferation has been noted upon DLL4 inhibition in normal mice as well [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/110\">",
"     110",
"    </a>",
"    ]. Demcizumab, an anti-DLL4 antibody, is in clinical trials. Inhibition of Notch and Jagged has also been proposed as a potential intervention for anti-angiogenic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947011\">",
"    <span class=\"h2\">",
"     Tie2/angiopoietin blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction of angiopoietins with the endothelial Tie2 tyrosine kinase is targeted by numerous agents in clinical trials including the peptibody AMG386 and the anti-angiopoietin-2 monoclonal antibody REGN910.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117146248\">",
"    <span class=\"h2\">",
"     COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;COX-2, an enzyme in the arachidonic acid cascade, is overexpressed in many tumors, both in the tumor mass and in the newly formed intratumoral blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/112\">",
"     112",
"    </a>",
"    ]. COX-2 inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) have a variety of effects on tumor and systemic vasculature.",
"   </p>",
"   <p>",
"    One mechanism whereby COX-2 overexpression might influence tumor biology is through effects on prostaglandin E2 (PGE-2), which can promote tumor growth and invasion via stimulation of VEGF, inhibition of immune surveillance, and upregulation of the antiapoptotic protein bcl-2 and various matrix metalloproteinases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Vascular disrupting agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative or complementary method for attacking tumor growth and integrity is via agents that directly disrupt existing tumor vessels. Vascular disrupting agents (VDAs) selectively damage the endothelial linings of tumor blood vessels, shutting off blood flow to the tumor, while leaving blood flow to normal tissues relatively intact [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/3,113-118\">",
"     3,113-118",
"    </a>",
"    ]. Finding genes that are overexpressed during malignant, but not physiologic, angiogenesis will be critical in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the major VDAs under investigation is combretastatin A4 phosphate (zybrestat, fosbretabulin), a novel tubulin depolymerizing agent capable of inducing rapid and selective vascular dysfunction in tumors, leading to tumor hypoxia and cellular death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. Early trials using this agent, and other microtubule-binding drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/124\">",
"     124",
"    </a>",
"    ], have linked its use with tumor responses in a variety of preclinical and clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/113,121-123,125,126\">",
"     113,121-123,125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional approach to disrupting tumor vascularity is that of causing selective thrombosis of tumor vessels, resulting in tumor infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. One example of this approach is the use of a truncated tissue factor fused to a protein that targets tumor-specific endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/60/1994/abstract/129\">",
"     129",
"    </a>",
"    ]. This fusion protein effectively inhibited tumor growth in mice by thrombotic occlusion of tumor vessels, without major side effects on other organs. It also showed inhibition of tumor perfusion in the first patients treated with this molecule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1539955\">",
"    <span class=\"h1\">",
"     TOXICITIES OF ANTIANGIOGENIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiangiogenic agents have a variety of cardiovascular and non-cardiovascular toxicities. Most of the cardiovascular toxicities appear to be related to the effects of these agents on non-tumor vasculature. Some of the toxicities of the tyrosine kinase inhibitors (TKIs) may be related to off-target effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11359541\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cancer Institute maintains a website at which updated information on clinical trials of angiogenesis inhibitors can be obtained:",
"    <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/search\">",
"     www.cancer.gov/clinicaltrials/search",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dependence of tumor growth on new blood vessel formation makes angiogenesis inhibition an extremely attractive approach for treating malignant disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of angiogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Anti-angiogenic therapy of cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular endothelial growth factor (VEGF) is the dominant growth factor controlling angiogenesis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vascular endothelial growth factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VEGF receptors (VEGFRs) are receptor tyrosine kinases expressed predominantly on endothelial cells that mediate angiogenesis; their pro-angiogenic roles can be inhibited by antibodies, small molecule tyrosine kinase inhibitors (TKIs), and soluble VEGF &ldquo;decoy&rdquo; receptors. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Anti-VEGF neutralizing antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Small molecule tyrosine kinase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VEGFR blockade may inhibit tumor growth by preventing endothelial cell proliferation, improving chemotherapy delivery by normalizing tumor vasculature, and reducing tumor edema. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mechanisms for clinical effects of VEGF inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional approaches to inhibiting tumor angiogenesis in clinical use or clinical development include endothelial growth factor receptor (EGFR) inhibitors; immunomodulatory drugs (IMiDs); HIF, DLL4 and",
"      <span class=\"nowrap\">",
"       Tie2/angiopoietin",
"      </span>",
"      inhibition; and vascular targeting agents. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Other antiangiogenesis approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiangiogenic agents have a variety of cardiovascular and non-cardiovascular toxicities. Most of the cardiovascular toxicities appear to be related to the effects of these agents on non-tumor vasculature. Some of the toxicities of the tyrosine kinase inhibitors (TKIs) may be related to off-target effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/1\">",
"      Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003; 95:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/2\">",
"      Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/3\">",
"      Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/4\">",
"      Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/5\">",
"      Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/6\">",
"      Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/7\">",
"      Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/8\">",
"      Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/9\">",
"      Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/10\">",
"      Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994; 266:H1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/11\">",
"      M&uuml;hlhauser J, Merrill MJ, Pili R, et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/12\">",
"      M&uuml;hlhauser J, Pili R, Merrill MJ, et al. In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Hum Gene Ther 1995; 6:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/13\">",
"      Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/14\">",
"      Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/15\">",
"      Zeng G, Taylor SM, McColm JR, et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 2007; 109:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/16\">",
"      Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/17\">",
"      Yen WC, Prudente RY, Corpuz MR, et al. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006; 94:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/18\">",
"      Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003; 102:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/19\">",
"      Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007; 13:5544s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/20\">",
"      Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 2012; 30:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/21\">",
"      Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/22\">",
"      Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/23\">",
"      Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/24\">",
"      Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/25\">",
"      Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/26\">",
"      Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/27\">",
"      Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990; 32:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/28\">",
"      Rifkin DB, Moscatelli D, Bizik J, et al. Growth factor control of extracellular proteolysis. Cell Differ Dev 1990; 32:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/29\">",
"      Tolnay E, Kuhnen C, Wiethege T, et al. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998; 124:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/30\">",
"      Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/31\">",
"      Prager GW, Breuss JM, Steurer S, et al. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/32\">",
"      Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/33\">",
"      Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/34\">",
"      Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 2000; 902:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/35\">",
"      Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/36\">",
"      Kuwai T, Kitadai Y, Tanaka S, et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003; 105:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/37\">",
"      Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/38\">",
"      Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/39\">",
"      Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13:5670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/40\">",
"      Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998; 79:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/41\">",
"      Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/42\">",
"      Pore N, Liu S, Haas-Kogan DA, et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003; 63:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/43\">",
"      Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001; 22:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/44\">",
"      Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/45\">",
"      von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/46\">",
"      Tosato G. Interferon-alpha is implicated in the transcriptional regulation of vascular endothelial growth factor. J Natl Cancer Inst 2003; 95:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/47\">",
"      McCarty MF, Bielenberg D, Donawho C, et al. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002; 19:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/48\">",
"      Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/49\">",
"      Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/50\">",
"      Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267:26031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/51\">",
"      Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15:5297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/52\">",
"      Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/53\">",
"      Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/54\">",
"      Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/55\">",
"      Suchting S, Eichmann A. Jagged gives endothelial tip cells an edge. Cell 2009; 137:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/56\">",
"      Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/57\">",
"      Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/58\">",
"      Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/59\">",
"      Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/60\">",
"      Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32A:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/61\">",
"      Menakuru SR, Brown NJ, Staton CA, Reed MW. Angiogenesis in pre-malignant conditions. Br J Cancer 2008; 99:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/62\">",
"      Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/63\">",
"      Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/64\">",
"      Stoll BR, Migliorini C, Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003; 102:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/65\">",
"      Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/66\">",
"      Semenza GL. A new weapon for attacking tumor blood vessels. N Engl J Med 2008; 358:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/67\">",
"      Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/68\">",
"      Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010; 10:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/69\">",
"      Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/70\">",
"      Khosravi Shahi P, Fern&aacute;ndez Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/71\">",
"      Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/72\">",
"      Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/73\">",
"      Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/74\">",
"      Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59:5209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/75\">",
"      Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007; 67:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/76\">",
"      Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/77\">",
"      Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003; 138:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/78\">",
"      Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/79\">",
"      Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/80\">",
"      Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res 2007; 67:7059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/81\">",
"      O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/82\">",
"      O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/83\">",
"      O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/84\">",
"      Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/85\">",
"      Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/86\">",
"      Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/87\">",
"      Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/88\">",
"      Jain RK, Munn LL. Vascular normalization as a rationale for combining chemotherapy with antiangiogenesis agents. Principles and Practice of Oncology Updates 2007; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/89\">",
"      Pries AR, H&ouml;pfner M, le Noble F, et al. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 2010; 10:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/90\">",
"      P&agrave;ez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/91\">",
"      Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/92\">",
"      Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/93\">",
"      De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/94\">",
"      Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15:5020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/95\">",
"      Sessa C, Guibal A, Del Conte G, R&uuml;egg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008; 5:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/96\">",
"      Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010; 102:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/97\">",
"      Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J 2011; 17:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/98\">",
"      Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/99\">",
"      Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13:5341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/100\">",
"      Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/101\">",
"      Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/102\">",
"      Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/103\">",
"      Barnes CJ, Bagheri-Yarmand R, Mandal M, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/104\">",
"      Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012; 136:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/105\">",
"      Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012; 9:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/106\">",
"      Patnaik A, Chiorean EG, Tolcher A, et al. EZN-2968, a novel hypoxia-inducible factor-1alpha (HIF-1alpha) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies (abstract 2564). J Clin Oncol 2009; 27:124s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/107\">",
"      Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/108\">",
"      Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/109\">",
"      Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/110\">",
"      Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010; 463:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/111\">",
"      Benedito R, Roca C, S&ouml;rensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009; 137:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/112\">",
"      Dormond O, R&uuml;egg C. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. Thromb Haemost 2003; 90:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/113\">",
"      O'Hanlon LH. Taking down tumors: vascular disrupting agents entering clinical trials. J Natl Cancer Inst 2005; 97:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/114\">",
"      Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/115\">",
"      Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006; 107:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/116\">",
"      Bix G, Castello R, Burrows M, et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 2006; 98:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/117\">",
"      Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/118\">",
"      Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009; 14:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/119\">",
"      Seaman S, Stevens J, Yang MY, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/120\">",
"      Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009; 100:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/121\">",
"      Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004; 13:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/122\">",
"      El-Emir E, Boxer GM, Petrie IA, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005; 41:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/123\">",
"      Cooney MM, Ortiz J, Bukowski RM, Remick SC. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep 2005; 7:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/124\">",
"      Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009; 15:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/125\">",
"      Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/126\">",
"      Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004; 93:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/127\">",
"      Ran S, Gao B, Duffy S, et al. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58:4646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/128\">",
"      Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/60/1994/abstract/129\">",
"      Bieker R, Kessler T, Schw&ouml;ppe C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009; 113:5019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2794 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1994=[""].join("\n");
var outline_f1_60_1994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF ANGIOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASCULAR ENDOTHELIAL GROWTH FACTOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of hypoxia and cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VEGF gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VEGF receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H946882\">",
"      Differential expression of VEGF receptors on tip cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VEGF in malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTI-ANGIOGENIC THERAPY OF CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      The angiogenic switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanisms for clinical effects of VEGF inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Inhibition of tumor endothelial proliferation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vascular normalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reduction of edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potential resistance to anti-angiogenic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biomarkers of angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ANTI-VEGF NEUTRALIZING ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SMALL MOLECULE TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H946928\">",
"      SOLUBLE VEGF &ldquo;DECOY&rdquo; RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OTHER ANTIANGIOGENESIS APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117146104\">",
"      EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117146124\">",
"      Imunomodulatory drugs (IMiDs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H946989\">",
"      Inhibition of hypoxia-inducible factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H946996\">",
"      Delta-like 4/Jagged Notch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H947011\">",
"      Tie2/angiopoietin blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H117146248\">",
"      COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Vascular disrupting agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1539955\">",
"      TOXICITIES OF ANTIANGIOGENIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11359541\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=related_link\">",
"      Pathogenesis and biology of malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_60_1995="Sliding scale 1";
var content_f1_60_1995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sliding scale 1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood glucose, mg/dl",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lispro insulin, units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80 to 139",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140 to 179",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        180 to 219",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;220",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1995=[""].join("\n");
var outline_f1_60_1995=null;
var title_f1_60_1996="Imm and nonimm anaphylx";
var content_f1_60_1996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanisms of anaphylaxis and pseudoallergic syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Proposed mechanism(s)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        IgE-mediated activation of mast cells and basophils",
"       </strong>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        &bull; Can be evaluated with skin test and/or in-vitro tests for allergen-specific IgE",
"       </p>",
"       <p>",
"        &bull; Usually requires prior exposure to allergen",
"       </p>",
"       <p>",
"        &bull; Potentially becomes more severe with repeat exposures",
"       </p>",
"       <p>",
"        &bull; Amenable to desensitization in some situations",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Examples: reactions to penicillin and other beta lactams, some neuromuscular blocking agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Immunologic mechanisms",
"        <em>",
"         NOT",
"        </em>",
"        involving IgE",
"       </strong>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        &bull; Formerly called anaphylactoid reactions",
"       </p>",
"       <p>",
"        &bull; Severity tends to remain constant with repeat exposures",
"       </p>",
"       <p>",
"        &bull; Skin testing and in-vitro testing are",
"        <strong>",
"         NOT",
"        </strong>",
"        useful",
"       </p>",
"       <p>",
"        &bull; Pretreatment with glucocorticoids and/or antihistamines may be helpful",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Examples: reactions mediated by IgG or IgM, antigen-antibody complexes, and/or complement proteins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Direct (non-immunologic) activation of mast cells and basophils",
"       </strong>",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        &bull; Severity tends to remain constant with repeat exposures",
"       </p>",
"       <p>",
"        &bull; Skin testing and in-vitro testing are",
"        <strong>",
"         NOT",
"        </strong>",
"        useful",
"       </p>",
"       <p>",
"        &bull; Pretreatment with glucocorticoids and/or antihistamines may be helpful",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Examples: reactions to radiocontrast agents, opioids, and some neuromuscular blocking agents",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1996=[""].join("\n");
var outline_f1_60_1996=null;
var title_f1_60_1997="IV medications for pediatric hypertensive emergencies";
var content_f1_60_1997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous drugs for treatment of hypertensive emergencies and urgencies in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose range&bull;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Onset of action",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration of action",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mechanism of action",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Labetalol",
"       </strong>",
"      </td>",
"      <td>",
"       Intravenous infusion or bolus",
"      </td>",
"      <td>",
"       <p>",
"        Bolus: 0.2- 1 mg/kg up to 40 mg/dose",
"       </p>",
"       <p>",
"        Infusion: 0.25-3 mg/kg/hr",
"       </p>",
"      </td>",
"      <td>",
"       2-5 min",
"      </td>",
"      <td>",
"       2-6 hr",
"      </td>",
"      <td>",
"       &alpha;- and",
"       <sub>",
"        &beta;",
"       </sub>",
"       - adrenergic blocker",
"      </td>",
"      <td>",
"       Contraindicated in asthma, BPD, HF and may mask symptoms of hypoglycemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Nicardipine",
"       </strong>",
"      </td>",
"      <td>",
"       Intravenous infusion",
"      </td>",
"      <td>",
"       0.5- 4 mcg/kg/min",
"      </td>",
"      <td>",
"       2-5 min",
"      </td>",
"      <td>",
"       30 min - 4 hr (increases with time of infusion)",
"      </td>",
"      <td>",
"       Calcium channel blocker",
"      </td>",
"      <td>",
"       May cause reflex tachycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hydralazine",
"      </td>",
"      <td>",
"       Intravenous bolus",
"      </td>",
"      <td>",
"       <p>",
"        IV: 0.2-0.6 mg/kg",
"       </p>",
"       <p>",
"        Maximum single dose: 20 mg",
"       </p>",
"      </td>",
"      <td>",
"       10 min (max effect may take up to 80 min)",
"      </td>",
"      <td>",
"       4-6 hours",
"      </td>",
"      <td>",
"       Direct vasodilator",
"      </td>",
"      <td>",
"       <p>",
"        May cause reflex tachycardia",
"       </p>",
"       <p>",
"        Variable response with potential for prolonged hypotension",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esmolol",
"      </td>",
"      <td>",
"       Intravenous infusion",
"      </td>",
"      <td>",
"       100-500 mcg/kg loading dose then 100-500 mcg/kg/min",
"      </td>",
"      <td>",
"       Immediate",
"      </td>",
"      <td>",
"       10-30 min",
"      </td>",
"      <td>",
"       <sub>",
"        &beta;",
"       </sub>",
"       - adrenergic blocker",
"      </td>",
"      <td>",
"       Contraindicated in asthma, BPD, HF and may cause profound bradycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fenoldopam",
"      </td>",
"      <td>",
"       Intravenous infusion",
"      </td>",
"      <td>",
"       0.1-2 &micro;g/kg/min",
"      </td>",
"      <td>",
"       5-40 min",
"      </td>",
"      <td>",
"       60 min",
"      </td>",
"      <td>",
"       Peripheral dopamine receptor agonist",
"      </td>",
"      <td>",
"       Limited experience in children",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nitroprusside",
"      </td>",
"      <td>",
"       Intravenous infusion",
"      </td>",
"      <td>",
"       0.5-10 mcg/kg/min",
"      </td>",
"      <td>",
"       Seconds",
"      </td>",
"      <td>",
"       Effect requires continuous infusion",
"      </td>",
"      <td>",
"       Venodilator with some arteriolar dilation",
"      </td>",
"      <td>",
"       <p>",
"        Monitor cyanide levels with prolonged (&gt;72 hr) use or coadminister sodium thiosulfate",
"       </p>",
"       <p>",
"        May increase ICP",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICP: intracranial pressure; BPD: bronchopulmonary dysplasia; HF: heart failure.",
"     <br>",
"      * Bolded medications are most commonly used for hypertensive emergencies in children.",
"      <br>",
"       &bull; See text for specific drug information about starting dose and recommended titration intervals.",
"       <br>",
"        &Delta; All agents may cause excessive hypotension.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Flynn, JT, Tullus, K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24:1101.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1997=[""].join("\n");
var outline_f1_60_1997=null;
var title_f1_60_1998="Recom doses of hepB vaccines";
var content_f1_60_1998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended doses of currently licensed formulations of hepatitis B vaccine, by age group and vaccine type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Single-antigen vaccine",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Combination vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Recombivax HB",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Engerix-B",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Comvax*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Pediarix",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Twinrix&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Dose, &micro;g&loz;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose, &micro;g&loz;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose, &micro;g&loz;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose, &micro;g&loz;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose, &micro;g&loz;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Volume, mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infants (&lt;1 yr)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children (1-10 yrs)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"11\">",
"        Adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        11-15 yrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        10&sect;",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        11-19 yrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults (&ge;20 yrs)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"11\">",
"        Hemodialysis patients and other immunocompromised persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;20 yrs&yen;",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;20 yrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        40������",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        40������",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.0",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"       <td class=\"sublist_other\">",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br>",
"      * Combined hepatitis B- Haemophilus influenzae type b conjugate vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or after age 71 months.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Combined hepatitis B-diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or at age &ge;7 years.",
"       <br>",
"        &Delta; Combined hepatitis A and hepatitis B vaccine. This vaccine is recommended for persons aged &ge;18 years who are at increased risk for both hepatitis B virus and hepatitis A virus infections.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Recombinant hepatitis B surface antigen protein dose.",
"         <br>",
"          &sect; Adult formulation administered on a 2-dose schedule.",
"          <br>",
"           &yen; Higher doses might be more immunogenic, but no specific recommendations have been made.",
"           <br>",
"            ������ Dialysis formulation administered on a 3-dose schedule at age 0, 1, and 6 months.",
"            <br>",
"             ������ Two 1.0-mL doses administered at one site, on a 4-dose schedule at age 0, 1, 2, and 6 months.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54 (RR-16):1.",
"       </li>",
"       <li>",
"        Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined] Prescribing Information. Glaxo SmithKline, 2003.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1998=[""].join("\n");
var outline_f1_60_1998=null;
var title_f1_60_1999="Palpation of internal pterygoid";
var content_f1_60_1999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of internal pterygoid muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with temporomandibular disorder, the internal pterygoid muscle may be tender on the affected side. The muscle is palpated on the inner aspect of the ramus of the mandible, between the tonsillar pillars. Each side is compared for pain reproduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_60_1999=[""].join("\n");
var outline_f1_60_1999=null;
